Section 3 of 6
Product information and disease description
403 evidence topics · 175 sources
Product description
Phase of product development
Regulatory status: Under review; NDA submitted in the third quarter of 2026
Launch
No evidence found.
Commercial preparation for a potential U.S. launch
Investigational status
FDA agreement to review the NDA under the Real-Time Oncology Review program
FDA acceptance, priority review, and action date
No evidence found.
Accelerated approval on progression-free survival with overall survival for full approval
FDA orphan drug designation for uveal melanoma, April 2022
| Field | Quoted record |
|---|---|
| Generic name | “darovasertib” |
| Date designated | “04/27/2022” |
| Orphan designation | “Treatment of Uveal Melanoma” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “IDEAYA Biosciences Inc.” |
Fast Track designation for darovasertib with crizotinib in metastatic uveal melanoma, November 2022
Breakthrough Therapy designation for neoadjuvant monotherapy in primary uveal melanoma, March 2025
FDA designations as summarized by the company, October 2026
European Union orphan designation for uveal melanoma, August 2025
Origin at Novartis and the 2018 license to IDEAYA
“Herein, we describe the discovery of darovasertib (NVP-LXS196), a potent pan-PKC inhibitor with high whole kinome selectivity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LXS196 is being investigated in the clinic as a monotherapy and in combination with other agents for the treatment of uveal melanoma (UM), including primary UM and metastatic uveal melanoma (MUM).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Servier license for rights outside the United States, August 2025
Patent protection for darovasertib
Adjuvant setting: OptimUM-11 phase 3 trial of darovasertib with crizotinib, first participant dosed in September 2026
Neoadjuvant setting: closure of the OptimUM-10 phase 3 trial
Cash, cash runway, and financing
NDA submission in progress with completion expected in the second half of 2026, September and October 2026, superseded in November 2026
Rolling NDA submission under RTOR with completion expected in the second half of 2026, April to August 2026, superseded in November 2026
NDA submission planned for the second half of 2026, April 2026, superseded in November 2026
OptimUM-02 topline results expected in the first quarter of 2026, January to March 2026, superseded in April 2026
Adjuvant setting: OptimUM-11 initiation planned for the first half of 2026 with a placebo comparator, February 2026, superseded in September 2026
Neoadjuvant setting: OptimUM-10 enrollment planned for completion in 2027, February and May 2026, superseded in November 2026
Product information
Generic, brand name and therapeutic class of product
Manufacturer: IDEAYA Biosciences
Nonproprietary name and development codes
| Substance record field | Quoted record |
|---|---|
| Preferred substance name | “DAROVASERTIB” |
| United States Adopted Name | “DAROVASERTIB [USAN]” |
| International Nonproprietary Name | “darovasertib [INN]” |
| WHO Drug Dictionary name | “Darovasertib [WHO-DD]” |
| Development code synonyms | “IDE196”; “LXS196”; “NVP-LXS-196” |
| Molecular formula | “C22H23F3N8O” |
Therapeutic class of darovasertib as described by the company
Brand name of darovasertib
No evidence found.
Combination partner: crizotinib (XALKORI), a kinase inhibitor marketed by Pfizer
Dosage forms and strengths
Investigational darovasertib tablet and crizotinib capsule in the OptimUM-02 trial
| Product | Pharmaceutical form | Route | Maximum daily dose (mg) |
|---|---|---|---|
| Darovasertib | “IDE196 (LXS196)”; “TABLET” | “ORAL” | “600” |
| Crizotinib | “Crizotinib 200mg hard capsules”; “CAPSULE, HARD” | “ORAL” | “400” |
Earlier darovasertib powder-in-capsule formulation in the OptimUM-01 trial
Darovasertib tablet strengths and commercial formulation
No evidence found.
Crizotinib (XALKORI) dosage forms and strengths
Crizotinib (XALKORI) capsule composition, including gelatin shells
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
AHFS patient medication information class of crizotinib
Crizotinib established class in the prescribing information
WHO Anatomical Therapeutic Chemical classification of crizotinib
| ATC code | Name | Defined daily dose | Unit | Route |
|---|---|---|---|---|
| “L01ED01” | “crizotinib” | “0.5” | “g” | “O” |
NCI Drug Dictionary classification of darovasertib
AHFS and ATC classification of darovasertib
No evidence found.
Indication
Population of the NDA under Real-Time Oncology Review
Indication pursued in the pivotal trial as described by the company
HLA-A∗02:01-positive OptimUM-01 data included in the NDA to support a broader labeled indication
Crizotinib (XALKORI) FDA-approved indications
Pharmacology
Mechanism of action
Protein kinase C signaling downstream of mutant GNAQ and GNA11
“A key downstream player of the constitutively active G-protein alpha subunits (GNAQ or GNA11) is the phospholipase C/protein kinase C (PKC) signalling pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PKC signalling is a key node in the maintenance of cellular homoeostasis; in UM cells, it results in phosphorylation and increased transcript expression of RasGrp3, a guanine nucleotide exchange factor that transduces signalling from GNAQ/GNA11 to the MAPK signalling pathway through PKC delta” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Darovasertib: oral, selective inhibitor of classical and novel PKC isoforms
Second-generation PKC inhibitor with activity restricted to GNAQ- or GNA11-mutant uveal melanoma cell lines
“LXS196 is a potent, second-generation, oral PKC inhibitor designed with improved pharmaceutical properties compared with AEB071.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LXS196 has a highly selective kinase profile affording increased tolerability in preclinical studies, with cellular activity restricted to UM cell lines containing mutant GNAQ or GNA11 and no activity observed in skin-derived melanoma cell lines driven by mutant B-Raf or N-Ras” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for combined PKC and MET inhibition: hepatocyte growth factor in the liver and MET overexpression
Crizotinib label: inhibition of ALK, c-Met, ROS1, and RON receptor tyrosine kinases
Pharmacodynamics
Reduction of pMARCKS and pPKC delta in tumor biopsies and peripheral blood mononuclear cells in the first-in-human study
“LXS196 reduced pMARCKS and phosphorylated PKC delta (pPKC delta), suggesting target engagement in on-treatment tumour biopsies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reduction in pPKC delta in PBMCs was observed within 6 h post-dose at all dose levels (Fig. 2a, b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (range) reduction in percentage change from baseline to C1D15 (normalised ratio) for pPKC delta and pMARCKS was −68.1 (−91.4, −28.6) and −39.7 (−89.7, 199), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No association between the extent of pMARCKS or pPKC delta suppression and dose group in the first-in-human study
“A decrease in pMARCKS/MARCKS was observed by C1D15 in patient tumour samples; however, no clear associations were detected between the extent of pMARCKS suppression and LXS196 treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Consistent with this, a decrease in pPKCd was observed by C1D15, but no correlation was seen between the extent of suppression and the LXS196 treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The decrease in pPKCd was also observed in PBMCs, which are not expected to carry mutations in the GNAQ/GNA11 pathway.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
RasGRP3 and DUSP6 expression in the first-in-human study
“RasGRP3 was decreased in some patients receiving LXS196 both QD and BID (Supplementary Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Levels of RasGRP3 at screening and after treatment also correlate with the best percent change in tumour volume from baseline (Supplementary Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MAPK pathway activity as measured by DUSP6 expression showed a trend towards suppression in the PR group (Supplementary Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory analysis of RasGRP3 reveals a potential biomarker for predicting efficacy and evidence of a transcriptional regulatory feedback on RasGRP3 by PKC inhibition and warrants further investigation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical tumor regression in the 92.1 uveal melanoma xenograft model
“When assessed in the 92.1 human UM mouse xenograft model, LXS196 dosed as a single agent leads to tumour regression at doses below its maximum tolerated dose (MTD), in contrast to AEB071, which achieves only stasis in this model” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Preclinical synergy of darovasertib and crizotinib in the presence of hepatocyte growth factor
Crizotinib label: QTcF change from baseline in an ECG substudy
Pharmacokinetics
Absorption and terminal half-life of single-agent darovasertib under fasting conditions
“During the dose escalation part of the study, following oral doses of 100–1000 mg QD and 200–400 mg BID, total plasma concentration profiles of LXS196 showed rapid absorption in fasting conditions with a Tmax of ~1 h after dose (median Tmax ranging from 0.483–2.00 h) and consistent terminal T1/2 across different doses (~11 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean terminal half-life (T1/2) was consistent across tested dose groups ranging from 8.49–13.8 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Accumulation, variability, and dose proportionality of single-agent darovasertib
“Minimal or reduced accumulation was observed with repeated administration (mean Racc ranged from 0.718 to 1.27-fold).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PK variability was moderate, as illustrated by the between-patient variability (CV%) for Cmax and for AUC0–t.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increase in exposure (AUC0–t and Cmax) on C1D1 and D15 was under-proportional to the increase in dose with both QD and BID schedules.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic sampling and parameters in the first-in-human study
“In the dose escalation part of the study, PK samples were collected at various pre- and post-dose time points on C1D1, D2, D3, D15 and D16.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PK parameters included area under the curve (AUC0–12h), maximum concentration (Cmax) and time to Cmax (Tmax) on C1D1 and C1D15, and additionally, the accumulation ratio (Racc) of AUC0–t on C1D15 compared to that on C1D1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Absorption and tolerability in preclinical species
Pharmacokinetic endpoints in the OptimUM-02 EU trial record
Darovasertib pharmacokinetics in combination with crizotinib
No evidence found.
Crizotinib label: steady state, absorption, and effect of food
Crizotinib label: distribution, elimination, metabolism, and excretion
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information for darovasertib
Not applicable.
Crizotinib label: hepatotoxicity, with liver function monitoring every 2 weeks for the first 2 months
Crizotinib label: interstitial lung disease and pneumonitis, with permanent discontinuation for drug-related disease
Crizotinib label: QT interval prolongation, with ECG and electrolyte monitoring
Crizotinib label: bradycardia, with heart rate and blood pressure monitoring and review of bradycardic and antihypertensive medications
Crizotinib label: severe visual loss and visual disorders, with monthly assessment of visual symptoms
Crizotinib label: gastrointestinal toxicity in pediatric and young adult patients with ALCL or IMT
Crizotinib label: embryo-fetal toxicity
Special populations
Crizotinib label: pregnancy
Crizotinib label: lactation
Crizotinib label: pregnancy testing, contraception, and infertility
Crizotinib label: geriatric use
Crizotinib label: hepatic impairment, with dose reduction for moderate or severe impairment
Crizotinib label: renal impairment, with dose reduction for severe impairment not requiring dialysis
OptimUM-02 EU trial record: renal and hepatic function thresholds
OptimUM-02 EU trial record: cardiac exclusions and heart rate threshold
OptimUM-02 EU trial record: contraception for 6 months in women and 3 months in men after the last dose
Darovasertib pharmacokinetics in hepatic or renal impairment
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on Darovasertib
OptimUM-01 drug interaction cocktail substudy: CYP3A4/5 and P-gp inhibitors and CYP3A4/5 inducers prohibited before dosing
Clinical drug interaction studies with darovasertib as the affected drug
No evidence found.
Crizotinib label: strong and moderate CYP3A inhibitors and grapefruit
Crizotinib label: strong CYP3A inducers
Crizotinib label: gastric acid reducing agents and P-glycoprotein
Effects of Darovasertib on other drugs
OptimUM-01 pravastatin and drug interaction cocktail substudies: planned pharmacokinetic outcome measures
OptimUM-01 pravastatin and drug interaction cocktail substudies: exclusion of interacting drugs and probe substrates
Results of the pravastatin and drug interaction cocktail substudies
No evidence found.
Overlapping adverse events of darovasertib and crizotinib in the OptimUM-01 first-line cohort
Crizotinib label: CYP3A substrates
Crizotinib label: drugs that prolong the QT interval or cause bradycardia
Crizotinib label: in vitro inhibition of CYP enzymes and transporters
Dosing and administration
Dosage
OptimUM-02 dose optimization arms and the selected combination dose in the registry record
OptimUM-02 randomized regimen: darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily
OptimUM-01 first-line cohort: recommended phase 2 dose and delivered dose intensity
Crizotinib label: recommended dosage of 250 mg twice daily for adults with NSCLC
Crizotinib label: dose reduction levels for adults, with 200 mg twice daily as the first reduction
| Dose reduction level for adult patients with NSCLC or IMT | Dose and schedule |
|---|---|
| First dose reduction | “200 mg twice daily” |
| Second dose reduction | “250 mg once daily” |
Crizotinib label: dosage modification for hematologic toxicities in adults
| Severity of hematologic adverse reaction in adult patients with NSCLC or IMT | Dosage modification |
|---|---|
| Grade 3 | “Withhold until recovery to Grade 2 or less, then resume at the same dosage.” |
| Grade 4 | “Withhold until recovery to Grade 2 or less, then resume at next lower dosage.” |
Administration
Supportive measures for hypotension during initial dosing of darovasertib with crizotinib
Crizotinib label: administration with or without food, missed doses, and vomiting
Access and distribution
Expanded access
U.S. commercialization plans and specialty sales force
Commercialization outside the United States by Servier
Manufacturing, packaging, and distribution through contract manufacturers
Guideline and compendia listing as a route to payer coverage in HLA-A∗02:01-positive disease
Specialty pharmacy distribution, pricing, and patient assistance
No evidence found.
Co-prescribed/Concomitant therapies
Crizotinib supplied by Pfizer for the combination trials
Concomitant medications excluded in the OptimUM-02 trial: CYP3A4/5, P-gp and BCRP substrates, and QT-prolonging drugs
Antihypertensive and other blood pressure-lowering medications in the single-agent LXS196 study
“Active management of symptomatic hypotension was recommended per protocol and regular vital signs (including blood pressure and heart rate) and ECG monitoring were required throughout the study at regular study visits.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Investigators were encouraged to temporarily withhold concomitant medications that may cause hypotension prior to the first dose of LXS196 and implement more frequent blood pressure monitoring throughout the study as deemed necessary per clinical need.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antidiarrheal prophylaxis with the darovasertib and crizotinib combination
No evidence found.
Effect of Darovasertib on quality measures
Scope of the MIPS melanoma recurrence measure
Product-specific effects on healthcare quality measures
No evidence found.
Product comparison
Competing products and development programs in uveal melanoma named by the sponsor
Treatments used in practice for advanced uveal melanoma: NICE committee description
Treatments used in practice for metastatic uveal melanoma: CADTH description of off-label immunotherapy
Tebentafusp label: HLA-A∗02:01-positive indication and genotyping requirement
Tebentafusp label: weekly intravenous step-up dosing until progression
Tebentafusp label: administration setting, post-infusion monitoring, and two-step dilution
Tebentafusp label: boxed warning for cytokine release syndrome and its incidence in IMCgp100-202
Tebentafusp label: skin reaction and liver enzyme warnings in IMCgp100-202
Tebentafusp label: IMCgp100-202 design and population of 378 participants
Tebentafusp label: IMCgp100-202 efficacy results versus investigator’s choice
| Outcome | KIMMTRAK (N=252) | Investigator’s choice of pembrolizumab, ipilimumab, or dacarbazine (N=126) |
|---|---|---|
| Overall survival, number of deaths (%) | “87 (34.5%)” | “63 (50%)” |
| Overall survival, median in months (95% CI) | “21.7 (18.6, 28.6)” | “16 (9.7, 18.4)” |
| Progression-free survival, median in months (95% CI), final analysis | “3.3 (3, 5)” | “2.9 (2.8, 3)” |
| Objective response rate (95% CI), not formally tested | “9.1% (5.9, 13.4)” | “4.8% (1.8, 10.1)” |
| Complete response | “1 (0.4%)” | “0” |
| Partial response | “22 (8.7%)” | “6 (4.8%)” |
| Comparison, KIMMTRAK versus investigator’s choice | Hazard ratio (95% CI) |
|---|---|
| Overall survival, prespecified interim analysis, stratified by LDH status | “0.51 (0.37, 0.71)” |
| Progression-free survival, final analysis, stratified by LDH status | “0.73 (0.58, 0.94)” |
Tebentafusp label: serious adverse reactions and discontinuation among patients who received KIMMTRAK in IMCgp100-202
Melphalan hepatic delivery system label: liver-directed indication restricted by hepatic tumor burden
Melphalan hepatic delivery system label: intra-arterial dosing every 6 to 8 weeks for up to 6 infusions
Melphalan hepatic delivery system label: boxed warning, general anesthesia, and REMS-certified settings
Melphalan hepatic delivery system label: FOCUS single-arm efficacy in 91 treated participants
| Outcome in the FOCUS trial | HEPZATO (N=91) |
|---|---|
| Objective response rate (95% CI) | “36.3% (26.4, 47.0)” |
| Complete response | “7.7%” |
| Partial response | “28.6%” |
| Number of responders | “n= 33” |
| Median duration of response, months (95% CI) | “14.0 (8.3, 17.7)” |
Melphalan hepatic delivery system label: serious and fatal adverse reactions and myelosuppression in FOCUS
Nivolumab label: melanoma indication and dosing with ipilimumab
Nivolumab label: ocular melanoma excluded from the first-line CHECKMATE-066 trial
Nivolumab label: serious adverse reactions with nivolumab plus ipilimumab in CHECKMATE-067 and the immune-mediated adverse reaction warning
Ipilimumab label: melanoma indication and combination dosing with nivolumab
Ipilimumab label: ocular melanoma excluded from CHECKMATE-067 and immune-mediated adverse reactions
Pembrolizumab label: melanoma indication, dose, and uveal melanoma excluded from KEYNOTE-002
Nivolumab and relatlimab label: melanoma indication, dose, and uveal melanoma excluded from RELATIVITY-047
Dacarbazine label: metastatic malignant melanoma indication, boxed warning, and intravenous dosing
Dacarbazine label: nausea and vomiting, myelosuppression, and administration setting
RP2 plus nivolumab versus nivolumab plus ipilimumab: phase 2/3 trial in immune checkpoint inhibitor-naive metastatic uveal melanoma
Place of product in therapy
Disease description
Definition and etiology
Definition of uveal melanoma and its sites of origin
Race, ethnicity, and iris color as risk factors
“UM affects non-Hispanic white patients 18 times more frequently than black patients and 15 times more than Asian patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grey/blue-eyed coloured irises are at higher risk than brown-eyed coloured irises.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Familial uveal melanoma and germline BAP1 and MBD4 variants
“About 2%-5% of UMs are considered familial and are mainly associated with germline mutations in the tumour-suppressor gene BAP1 and less frequently with an MBD4 pathologic variant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Germline mutations in BAP1 have been identified as being responsible for the BAP1 tumour predisposition syndrome (BAP1-TPDS), which is associated with UM, mesothelioma, cutaneous melanoma and renal cell carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: fair skin, light eye color, ocular melanocytosis, and BAP1 tumor predisposition syndrome
Nevus of Ota as a risk factor
Epidemiology
Incidence of metastatic uveal melanoma
U.S. age-adjusted incidence of uveal melanoma, SEER core registries, 1975 to 2020
“The overall mean age-adjusted incidence of primary uveal melanoma in the US over the 45-year period from 1975 to 2020 was 5.6 per million population (95% CI: 5.5–5.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As previously noted, a small but statistically significant (p < 0.05) annual percentage change of 0.5% was detected in whites.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age-adjusted incidence of uveal melanoma by sex
Incidence of uveal melanoma by race, ethnicity, sex, and age in 37,917 cases
“A total of 37,917 UM cases were identified, with an overall AAIR of 5.54 per million (95% CI: 5.48-5.59), showing a stable but slightly increasing trend (AAPC = 0.06).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence was highest in non-Hispanic whites (6.87 ppm), men (6.25 ppm), and those aged 75-79 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual age-adjusted incidence of uveal melanoma by race and ethnicity
U.S. age-adjusted incidence of uveal melanoma and sex difference, NCI PDQ summary
Age at diagnosis of uveal melanoma
“Median age at diagnosis was 63 years (range: 5–90 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“UM occurs in patients of all ages; 1% of cases affect the paediatric population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence increases with age, rising to >20 cases per million by the age of 70.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated U.S. new cases in 2026, all eye and orbit cancer
| Site, United States, 2026 | Estimated new cases, both sexes | Male | Female |
|---|---|---|---|
| Eye and orbit | “3200”View highlighted excerpt for this quote | “1720”View highlighted excerpt for this quote | “1480”View highlighted excerpt for this quote |
Worldwide geographic variation in incidence
“In a recent study, incidence that correlated with latitude was expressed as a north-to-south decreasing gradient, ranging from ≥8.0 cases per million person-years in Northern/Western Europe and Oceania, to 2.0-7.9 in North America, Eastern Europe and Southern Europe and <2.0 in South America, Asia and Africa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
SEER stage at diagnosis of uveal melanoma
| SEER stage at diagnosis, uveal melanoma | N (%) |
|---|---|
| Localized | “6,126 (90.9)”View highlighted excerpt for this quote |
| Regional | “506 (7.5)”View highlighted excerpt for this quote |
| Distant | “109 (1.6)”View highlighted excerpt for this quote |
Detectable metastases at diagnosis of the primary tumor
“Of 3610 patients with uveal melanoma, 69 (1.9%; 95% CI 1.5 to 2.4) presented with clinical metastasis (stage IV).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Risk of synchronous metastases increased from 0.7% (T1) to 1.5% (T2), 2.6% (T3) and 7.9% (T4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of patients who develop metastases after treatment of the primary tumor
“Although local therapy is effective for local control in >90% of cases, up to 50% of patients will develop metastases, mainly in the liver (90%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unfortunately, up to 50% of patients with uveal melanoma will ultimately develop metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment of primary uveal melanoma with radiotherapy, enucleation or other modalities achieves local control in more than 90% of patients, although 40% or more ultimately develop distant metastases, most commonly in the liver.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cumulative incidence of metastasis at 5 and 10 years, COMS trials
“Seven hundred thirty-nine patients were diagnosed with at least 1 site of metastasis during follow-up after treatment for choroidal melanoma. Five- and 10-year cumulative metastasis rates were 25% (95% confidence interval, 23%-27%) and 34% (95% confidence interval, 32%-37%), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Risk of metastasis by AJCC stage and tumor thickness
“The AJCC Cancer Staging Manual is an anatomy-based system; tumour diameter and thickness, ciliary body involvement and extraocular extension are factors associated with the risk of metastasis at 10 years from 5% for stage I to 40% for stage III.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Small thickness UM (0-3 mm in thickness) was associated with a 5- and 10-year metastatic risk of 6% and 12%. The 5-/10-year metastatic risk of medium thickness (3.1-8 mm) and large tumors (>8 mm in thickness) was 14%/26% and 35%/49%, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annual number of new U.S. cases of metastatic uveal melanoma
No evidence found.
Prevalence of metastatic uveal melanoma
EU prevalence of uveal melanoma at orphan designation of tebentafusp
U.S. prevalence of uveal melanoma or of metastatic uveal melanoma
No evidence found.
HLA-A∗02:01 positivity in U.S. and European populations
HLA-A∗02:01 positivity by self-declared race among Brazilian bone marrow donors
“Considering the race of the patients tested, 22.5% of white individuals, 17.5% of black, 22.8% of indigenous, 20.4% of yellow, and 20.2% of brown/mixed were HLA-A*02:01-positive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to the presented data, the positiveness of HLA-A*02:01 in the Brazilian population is much lower when compared to the frequencies in North Americans and Europeans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HLA-A∗02011 share of HLA-A2 alleles in five U.S. population groups
“The most frequently detected HLA-A2 allele in all groups was HLA-A*02011.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Caucasian and Native American populations appear to be the most homogeneous exhibiting 95.7% and 94.3% A*02011, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HLA-A*0202 (25.8%) and A*0205 (12.9%) were present in a large percentage of African-Americans.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HLA-A∗02:01 frequency in uveal melanoma cohorts compared with the general population
“As a result, 10 haplotypes showed differences at a FDR of < 0.05 between uveal and population frequencies, of which nine showed higher frequency in uveal melanoma patients: HLA-A*01:01, HLA-A*02:01, HLA-B*08:01, HLA-B*15:01, HLA-B*18:01, HLA-B*44:02, HLA-C*01:02, HLA-C*05:01, HLA-C*07:01, HLA-C*12:03.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Five-year relative survival, all uveal melanoma, 1975 to 2016
Five-year and ten-year relative survival, all uveal melanoma
U.S. five-year relative survival by SEER stage, eye melanoma diagnosed 2015 to 2021
Estimated U.S. deaths in 2026, all eye and orbit cancer
| Site, United States, 2026 | Estimated deaths, both sexes | Male | Female |
|---|---|---|---|
| Eye and orbit | “530”View highlighted excerpt for this quote | “280”View highlighted excerpt for this quote | “250”View highlighted excerpt for this quote |
Long-term metastasis-free survival and melanoma-related death
“The KM estimates of MFS were 0.729 (0.719, 0.74), 0.648 (0.633, 0.663), and 0.616 (0.596, 0.636) at 10, 20, and 30 years, respectively. The cumulative probabilities of melanoma metastatic death at 10, 20 and 30 years were 0.241 (0.236, 0.245), 0.289 (0.283, 0.294), and 0.301 (0.295, 0.307).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Death due to melanoma were rare beyond 20 years with normal life expectancy reached at 25 years after primary therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Uveal melanoma-related mortality over 35 years and late metastatic death
“Uveal melanoma-related mortality was 31% (95% confidence interval [CI], 26-37) by 5 years, 45% (95% CI, 40-51) by 15 years, 49% (95% CI, 43-55) by 25 years, and 52% (95% CI, 45-58) by 35 years, according to cumulative incidence analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of patients who died of uveal melanoma, 62%, 90%, 98%, and 100% did so within 5, 15, 25, and 35 years, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Micrometastatic dormancy and late liver metastasis
“Metastatic liver disease is the overwhelming cause of death in uveal melanoma patients, with almost 50% of patients developing liver metastases up to 15 years after diagnosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most of these patients do not present with any evidence of overt metastasis at the time of initial diagnosis although it is assumed that they have undetectable micrometastases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prognosis after extraocular extension, recurrence, or metastasis
Course after metastasis: liver involvement, survival beyond 5 years, and cure rate
“Almost 50% of patients develop metastatic disease, which usually involves the liver, and is usually fatal within 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses confirm a median overall survival of 10-13 months, and a cure rate that approaches nil, although survival exceeding 5 years is possible, estimated 2% either with first-line treatment or with best supportive care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Death rate after diagnosis of metastasis, COMS trials
“The death rate following the report of melanoma metastasis was 80% at 1 year (95% confidence interval, 77%-83%) and 92% at 2 years (95% confidence interval, 89%-94%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term survival after diagnosis of metastasis was uncommon; only 8 patients survived 5 or more years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival after diagnosis of metastasis with and without treatment
“Overall, the median survival time was poor (3.9 months [IQR, 1.6-10.1]). Patients who received treatment fared better than those who did not receive treatment (median survival after metastasis diagnosis, 6.3 months [IQR, 2.96-14.41] vs 1.7 months [IQR, 0.66-3.5]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled overall survival after metastasis, meta-analysis of 78 articles with 2494 participants
“Individual-level data were obtained from 78 articles with 2494 patients. The median OS across all treatment modalities was 1.07 years (range: 0.59–2.50 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reported OS was unassociated with the decade of publication, but depended on the percentage of first-line treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression-free and overall survival benchmarks
“The median PFS was 3.3 months (95% CI 2.9-3.6) and 6-month PFS rate was 27% (95% CI 24-30).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was 10.2 months (95% CI 9.5-11.0) and 1 year OS was 43% (95% CI 40-47).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
One-year survival in a cohort with metastatic uveal melanoma
Overall survival with active treatment by working formulation stage
Prognostic factors after metastasis: lactate dehydrogenase, alkaline phosphatase, and liver metastasis size
“Univariable analysis showed male sex, elevated (i.e. > versus ≤ upper limit of normal) lactate dehydrogenase (LDH), elevated alkaline phosphatase (ALP) and diameter of the largest liver metastasis (≥3 cm versus <3 cm) to be substantially associated with shorter PFS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most substantial prognostic factors for shorter OS by univariable and multivariable analysis were elevated LDH and elevated ALP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The multivariable Cox analysis showed that slight to moderately elevated LDH (250–500 U/L) and high LDH level (>500 U/L) were a statistically significant factor associated with poor survival (p < 0.001), HR of 1.8 (95% CI 1.07–3.01) and 9.0 (95% CI 5.63–14.35) respectively. Also, the presence of liver metastases was negatively associated with survival, HR 2.09 (95% CI 1.07–4.08, p = 0.03).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Different staging systems predict survival after metastatic disease appears, based on tumour burden, liver function tests, World Health Organization performance status (PS) and metastasis-free interval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AJCC distant metastasis categories by largest metastasis diameter
Distribution of AJCC M categories in a nationwide Finnish cohort
Survival by mode of detection of metastasis
Delay before the effect of newer systemic therapies appears in SEER data
Pathophysiology
Activating GNAQ and GNA11 mutations
“Mutations in GNAQ, the gene encoding an alpha subunit of heterotrimeric G proteins, are found in 40% of uveal melanomas.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the uveal melanomas we analyzed, 83% had somatic mutations in GNAQ or GNA11.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GNA11 and GNAQ Q209 mutations in primary tumors and metastases
“The frequency of mutations in GNA11 at the codon encoding Q209 increased progressively from blue nevi (6.5%) to primary uveal melanomas (31.9%) to uveal melanoma metastases (56.5%), a pattern inverse to the distribution of Q209 mutations in GNAQ, which are most common in blue nevi (54.7%) and least common in uveal melanoma metastases (21.7%) (P<0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mutually exclusive G-protein pathway mutations: GNAQ, GNA11, CYSLTR2, and PLCB4
CYSLTR2 mutation as a uveal melanoma oncogene
“We analyzed genomics data from 136 uveal melanoma samples and found a recurrent mutation in CYSLTR2 (cysteinyl leukotriene receptor 2) encoding a p.Leu129Gln substitution in 4 of 9 samples that lacked mutations in GNAQ, GNA11, and PLCB4 but in 0 of 127 samples that harbored mutations in these genes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Leu129Gln CysLT2R mutant protein constitutively activates endogenous Gαq and is unresponsive to stimulation by leukotriene.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PLCB4 mutation as the downstream effector of Gαq signaling
Protein kinase C and MAPK pathway activation downstream of GNAQ and GNA11
“We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation, MAPK activation can be attributed to activated PKC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Second driver event: BAP1, SF3B1, or EIF1AX
“After the GNAQ/GNA11 mutation, a second driver event is necessary for malignant transformation. The premalignant cells either present loss of function BAP1 or mutations in SF3B1 or EIF1AX. This second hit also occurs in a mutually exclusive fashion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
BAP1 inactivation in metastasizing tumors and chromosome 3 loss
“Inactivating somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (BAP1) on chromosome 3p21.1 in 26 of 31 (84%) metastasizing tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One copy of chromosome 3 was missing in all 17 BAP1-mutant class 2 tumors for which cytogenetic data were available, consistent with chromosome 3 loss uncovering recessive BAP1 mutations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Four molecular subsets defined by chromosome 3 status, TCGA
“Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EIF1AX and SF3B1 mutations in 27 of the 80 UM (34%) were nearly mutually exclusive” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prognostic associations of BAP1, SF3B1, EIF1AX, MBD4, and PRAME
“Biallelic BAP1 inactivation is associated with high risk of metastasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Change-of-function SF3B1 mutations are associated with late metastasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mutations in EIF1AX are associated with a better prognosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mutations in MBD4 lead to a hypermutator phenotype, which has been correlated with improved response to immune checkpoint inhibitor (ICI) therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expression of PRAME (preferentially expressed antigen of melanoma) is associated with a higher risk of metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Low tumor mutational burden and absence of BRAF, NRAS, KIT, and NF1 mutations
Immunosuppressive tumor microenvironment
Hematogenous spread and liver tropism
“UM is characterised by early seeding and years of dormancy of micrometastases; the liver constitutes a specific niche, as numerous molecules like chemokine ligand 12 and chemokine receptor 4 (CXCL12/CXCR4) are involved in UM liver homing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
MET expression in primary tumors and liver metastases
“Thirty-nine of 40 (98%) primary tumors and nine of 10 (90%) metastatic liver lesions expressed c-MET (H-score range 0-300).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“c-MET expression was significantly higher in metastatic compared with primary tumors (median H-score 190 vs. 30, P=0.022).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Clinical diagnosis of the primary ocular tumor
Guideline recommendations on ocular imaging and biopsy of the primary tumor
“UM diagnosis is based on clinical examination by ophthalmoscopy, fundus photography and conventional ocular ultrasound (US) in patients presenting with blurred vision or other visual symptoms; however, 13%-30% are diagnosed during routine eye examinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biopsy is not mandatory for typical UM diagnosis, which is well characterised by ophthalmoscopy, fundus photography and conventional ocular US [II, D].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A biopsy is recommended if the clinical diagnosis is uncertain and if it has been discussed with the patient due to the potential risks of the procedure and the uncertainty of a conclusive result [II, A].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Staging and screening for distant metastases at diagnosis
“UM should be staged according to the eighth edition of the AJCC Cancer Staging Manual.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should be screened for distant metastases [liver US or MRI with diffusion-weighted sequences, supplemented by positron emission tomography (PET)–computed tomography (CT) or thoraco-abdomino-pelvic CT for extrahepatic extension].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Molecular prognostic testing of the primary tumor: methods and risk groups
“The most commonly used prognostic tests are FISH, multiplex ligation-dependent probe amplification, microsatellite analysis, single-nucleotide polymorphism array, array comparative genomic hybridisation, targeted NGS and a 12-gene PCR assay based on gene expression profiling (GEP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A low risk of metastasis is associated with tumours that have normal chromosomes 3 and 8; these tumours often display 6p gain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Late but infrequent metastatic spread is associated with normal chromosome 3, one or more extra copies of (partial) chromosome 8, GEP class 1 status and with PRAME expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A high risk of metastasis is associated with loss of one copy of chromosome 3 or isodisomy of this chromosome, polysomy of chromosome 8q, a GEP class 2 profile and inactivating mutations or deletions of the BAP1 gene located on chromosome 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gene expression profile class 1 and class 2: prospective multicenter validation
“The GEP assay successfully classified 446/459 (97.2%) cases. The GEP was class 1 in 276 cases (61.9%) and class 2 in 170 cases (38.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Metastasis was detected in 3 (1.1%) class 1 cases and 44 (25.9%) class 2 cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using multivariate Cox modeling, GEP class had a stronger independent association with metastasis than any other prognostic factor (P<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommended molecular work-up of primary and metastatic tumors
“If sufficient tumour material is available, the molecular work-up of primary UM could include copy number assessment in chromosomes 3, 6 and 8, GEP, mutational status of BAP1, SF3B1, EIF1AX, and immunohistochemistry for BAP1 and PRAME expression [III, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Assessment of mutational status of GNAQ, GNA11, SF3B1 and MBD4 may be recommended in the metastatic setting as results may impact treatment decisions [IV, C].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surveillance imaging of the liver after treatment of the primary tumor
“There is no prospective evidence that imaging surveillance impacts the outcomes of patients with UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Liver function tests have a low sensitivity and do not help detect early metastasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hepatic US has a sensitivity of 96% in detecting liver metastasis from UM but the positive predictive value (PPV) is only 45%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gadolinium-enhanced liver MRI with diffusion-weighted sequences has demonstrated sensitivity of nearly 100% and specificity of 80%-99%, with a better ability to detect small lesions compared with US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Genetic and clinical factors should be used to guide surveillance, as there is no standard approach to detecting metastases in patients with UM [III, A].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sensitivity of hepatic ultrasonography and MRI for surveillance
“Hepatic ultrasonography and magnetic resonance imaging as surveillance methods have a sensitivity of 95-100% and 83-100%, respectively, to detect metastases without radiation hazard according to prevailing evidence, but computed tomography is necessary for staging.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver function test screening for metastasis, COMS trials
“Based on all patients with reported metastasis, the sensitivity, specificity, positive predictive value and negative predictive value associated with at least one abnormal LFT before first diagnosis of metastasis at any site was 14.7%, 92.3%, 45.7% and 71.0%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Detection of metastases by screening ultrasonography and liver function tests
“Metastases were diagnosed in 74% of patients (95% confidence interval [95% CI], 59-86) at screening and in 26% (95% CI, 14-41) when the patient consulted a physician because of symptoms that developed before the next scheduled visit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“US was diagnostic in 78% (95% CI, 64-89), at least 1 LFT test was abnormal in 70% of patients (95% CI, 54-82), and a chest X-ray was abnormal in 2% of patients (95% CI, 0-12).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Staging imaging and biopsy confirmation of metastatic disease
“Staging of metastatic disease is based on total body CT scan and liver MRI; brain imaging is not required in the absence of central nervous system symptoms; the usefulness of fluorodeoxyglucose (FDG)–PET–CT is still debated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HLA-A∗02:01 testing in the metastatic setting
HLA-A∗02:01 companion diagnostic: specimen and sequencing method
Turnaround of HLA-A∗02:01 testing in practice
Clinical presentation - signs and symptoms
Visual symptoms: blurred vision, visual field defect, and photopsia before diagnosis of the primary tumor
| Symptom before diagnosis, 159 Finnish patients | Patients, n | Patients, % |
|---|---|---|
| Blurred vision | “78”View highlighted excerpt for this quote | “49”View highlighted excerpt for this quote |
| Visual field defect | “51”View highlighted excerpt for this quote | “32”View highlighted excerpt for this quote |
| Photopsia | “29”View highlighted excerpt for this quote | “18”View highlighted excerpt for this quote |
| Irritation and pain | “26”View highlighted excerpt for this quote | “16”View highlighted excerpt for this quote |
| Metamorphopsia | “10”View highlighted excerpt for this quote | “6”View highlighted excerpt for this quote |
| Floaters | “9”View highlighted excerpt for this quote | “6”View highlighted excerpt for this quote |
| Asymptomatic | “20”View highlighted excerpt for this quote | “13”View highlighted excerpt for this quote |
Ocular signs: retinal detachment and secondary angle-closure glaucoma
Asymptomatic primary tumors detected on routine examination
“Although UM patients typically present with symptoms including blurred vision, visual field defect, metamorphopsia, or photopsia, 30% patients may be asymptomatic and upon routine eye examination, they are detected incidentally.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular pain and vision loss in a case series of synchronous primary and metastatic disease
“Seventeen patients (81%) had ophthalmic symptoms at diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Common symptoms were loss of vision (n=12), myodesopsia (n=4), photopsia (n=3) and eye pain (n=5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic and constitutional symptoms: abdominal pain, anorexia, weight loss, and nausea at detection of metastasis
Physical signs of metastasis: hepatomegaly, lymphadenopathy, and subcutaneous nodules
“In 1985, the Collaborative Ocular Melanoma Study (COMS) employed a combination of physical examination for hepatomegaly, enlarged lymph nodes and subcutaneous nodules as well as ancillary chest X-rays and liver function tests.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory signs: elevated lactate dehydrogenase and alkaline phosphatase at diagnosis of metastasis
Neurological symptoms: brain metastases
“116/1,845 (6.3%) mUM patients were identified with BM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Brain imaging was obtained only upon onset of neurological symptoms in most cases of identified brain metastases and not for asymptomatic surveillance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term morbidity
Metastatic uveal melanoma as the leading cause of death
“The audited cause of death was uveal melanoma in 145 (61%) of them.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Metastatic uveal melanoma was the leading single cause of death throughout the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disability attributed to the condition: vision impairment, enucleation, pain, and organ failure
Metastatic sites at death, COMS large tumor trial
“A total of 269 patients (62%) had histopathologically confirmed melanoma metastasis at the time of death, and metastasis was suspected in 92 additional patients (21%) on the basis of imaging and tests but without tissue confirmation. The common sites were liver (93%), lung (24%), and bone (16%); multiple sites were identified in 87% of patients with metastasis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic and extrahepatic metastatic sites during follow-up
“Liver was the most common site (89%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Survival after symptomatic brain metastases
Primary tumor treatment: surgery and radiation trends, 1975 to 2020
“The previously reported declining trend in the number of patients treated with surgery alone (93% from 1975 to 1977 vs. 21% from 2017 to 2020) ensued, with ongoing corresponding increasing rates of radiation as the primary treatment (1% from 1975 to 1977 vs. 58% from 2017 to 2020).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enucleation of the affected eye
Radiation-related ocular complications: maculopathy, optic neuropathy, neovascular glaucoma, and cataract
“Any type of RT can lead to posterior complications such as maculopathy, optic neuropathy, neovascular glaucoma and retinopathy, which can have an impact on vision and eye preservation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the anterior segment of the eye, cataract and dry eye are the most common side-effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Signs of RT-induced maculopathy on fundus examination are detected in ≤66.5% of cases within 3 years of PBR.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity after iodine-125 brachytherapy, COMS medium tumor trial
“Three years after I(125) brachytherapy, median visual acuity was 20/125, with 34% having 20/40 or better and 45% having 20/200 or worse visual acuity, including eyes that were enucleated within 3 years of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychological morbidity: anxiety, depression, and worry about recurrence after prognostic testing
“Compared to other groups, survivors with poor prognoses showed initially elevated anxiety and depression and consistently elevated worry about local or distant recurrence over 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (SD) HADS anxiety score at baseline (7.4 [4.0]) was higher than at 3 months (5.4 [3.7]; P < .001) or 12 months (4.7 [3.4]; P < .001), and decreased with older age (coefficient estimate [SD], -0.06 [0.02]; P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychological burden of surveillance and of eye loss
“The discussion should include the emotional and organisational impact of this surveillance strategy as well as its frequency and duration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“QoL is affected by specific concerns, including recurrence and loss of the eye or visual impairment. These need to be considered by ophthalmologists and oncologists, who should provide appropriate care, including psychological support, as depressive symptoms are common after ocular tumour treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of metastatic uveal melanoma
Humanistic burden and health-related quality of life
EORTC QLQ-C30 global health status and EQ-5D visual analogue scale in the IMCgp100-202 tebentafusp trial, intent-to-treat analysis set
| EORTC QLQ-C30 global health status (score 0 to 100) | Tebentafusp: participants assessed | Tebentafusp: mean | Tebentafusp: SD | Investigator's choice: participants assessed | Investigator's choice: mean | Investigator's choice: SD |
|---|---|---|---|---|---|---|
| Baseline (cycle 1) | “173” | “76.108” | “20.233” | “65” | “74.872” | “20.439” |
| Change from baseline at cycle 3 | “105” | “0.952” | “16.274” | “35” | “-0.238” | “14.919” |
| Change from baseline at cycle 5 | “94” | “-1.152” | “20.797” | “22” | “-10.227” | “22.557” |
| Change from baseline at cycle 9 | “57” | “-2.193” | “19.577” | “13” | “-8.333” | “13.176” |
| Change from baseline at end of treatment | “76” | “-10.417” | “20.911” | “34” | “-10.539” | “23.148” |
| EQ-5D visual analogue scale (score 0 to 100) | Tebentafusp: participants assessed | Tebentafusp: mean | Tebentafusp: SD | Investigator's choice: participants assessed | Investigator's choice: mean | Investigator's choice: SD |
|---|---|---|---|---|---|---|
| Baseline (cycle 1) | “194” | “81.0” | “16.36” | “78” | “80.4” | “18.31” |
| Change from baseline at cycle 3 | “136” | “0.4” | “14.69” | “45” | “-0.8” | “14.28” |
| Change from baseline at cycle 5 | “108” | “0.6” | “15.61” | “28” | “-0.7” | “14.38” |
| Change from baseline at cycle 9 | “71” | “-0.9” | “19.81” | “14” | “-3.3” | “13.30” |
| Change from baseline at end of treatment | “95” | “-10.1” | “22.53” | “45” | “-11.7” | “21.40” |
Health-related quality of life in a randomized phase 2 trial of selumetinib versus chemotherapy
“Data from a phase II trial (clinicaltrials.gov identifier: NCT01143402) where patients with metastatic uveal melanoma were randomized to receive selumetinib, an oral MEK inhibitor, or chemotherapy were analyzed. Patients reported HRQoL at baseline, after 1 month, and end of treatment (n = 118), whereas physicians adjudicated AEs via CTCAE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean HRQoL scores did not significantly differ at each of the three time points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Emotional impacts and treatment burden reported in qualitative interviews
“Seventeen patients and 16 clinicians participated in the study. All patients were on anti-cancer treatment at the time of being interviewed, except for three who were deliberating treatment options.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients placed greater emphasis on the emotional, rather than physical, impacts of disease and treatment. Emotional concerns were centred on the existential threat posed by metastatic disease within the context of uncertainty about treatment access and effectiveness. More variably, patients were concerned with burden from treatment in the form of time commitment, travel, need for hospitalisation, and expense. Of the treatments received, immunotherapy – especially tebentafusp – conferred the heaviest inconvenience and symptom burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Role functioning/well-being was impacted by symptoms and treatment burden, with several patients reducing or ceasing employment or more physically demanding leisure activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety before and after surveillance and response scans
“Fear of disease progression was most often manifest as a preoccupation with investigative tests as an indicator of treatment efficacy and the need to seek alternatives. Feelings of anxiety increased from a few days leading up to a test to when results were received. Patients’ experience of time waiting for results varied from 1 day to 3 weeks, depending on whether they needed to schedule an appointment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most participants were able to maintain everyday normalcy but struggled to discuss their illness and treatment with family and friends. Participants reported heightened anxiety in the lead-up to routine scans and while awaiting results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Distress trajectories and worry about recurrence in uveal melanoma survivors
“In a closed cohort study, we used growth mixture modeling (GMM) to identify statistically optimal trajectories over 6-, 12-, 24-, 36-, 48-, 60-, 72-, and 84-month time point posttreatment in 475 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The majority scored consistently low, but 17.5% showed consistently elevated anxiety, 10.9% consistently elevated depression, and 19.4% consistently elevated FCR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Non-randomized 5-year study of a consecutive series of 708 UM survivors (51.6% male, mean age 69.03, SD=12.12) with observations at 6, 12, 24, 36, 48 and 60 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Generally, no prognostic groups reported anxiety, depression and WREC or QoL scores that exceeded general population norms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality of life after melphalan percutaneous hepatic perfusion
“Twenty-four patients (14 males; median age 63.0 years) completed 96 questionnaires. Most scores on all scales declined on day 2/3 after M-PHP. On day 21 after M-PHP, 12 out of 15 scores returned to baseline, including median GHS scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three variables were significantly worse on day 21 compared to baseline: fatigue (6–33; p = 0.002), physical functioning (100 vs 86.7; p = 0.003), and role functioning (100 vs 66.7; p = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Retrospective analysis of the change in QoL using the Functional Assessment of Cancer Therapy-General (FACT-G) with mUM patients receiving M-PHP (n = 20).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline FACT-G median (IQR) scores were 101.8 (21.8). QoL scoring significantly decreased immediately after the procedure [day 1; 85 (27.5); P = 0.002] and gradually improved over time. By day 28, QoL almost returned to pre-procedure levels [100.3 (13.8); P = 0.31].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EQ-5D-3L health status and health utility after isolated hepatic perfusion, SCANDIUM trial
“HRQOL was measured by the EuroQol 5-domains 3-levels (EQ-5D-3L) questionnaire over 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Throughout the 12-month follow-up period, the VAS scores remained stable in the IHP group but there was a decrease in the control group at 6 months (83 vs. 64, P=0.002) and 12 months (86 vs. 63), P=0.002) (Fig. 4A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were similar findings for health utility as measured by EQ-5D-3L, with a significant difference between IHP and controls at 6 months (0.87 vs. 0.70, P=0.019) and 12 months (0.88 vs. 0.66, P=0.005) (Fig. 4B). However, this difference was not significant when adjusting for baseline health utility scores with a mean change from baseline at 6 months of −0.02 versus −0.10 (P=0.36) and at 12 months −0.02 versus −0.08 (P=0.49).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
All-cause healthcare costs and resource use in U.S. commercial, Medicare, and Medicaid claims
Healthcare costs by treatment type and adverse event-related costs in U.S. commercial and Medicare claims
| Treatment group (Commercial and Medicare patients) | Mean all-cause healthcare costs per patient per month (2025 US$) | Mean adverse event-related costs per patient per month (2025 US$) | Adverse event-related costs as a percentage of all-cause costs |
|---|---|---|---|
| All patients (n=423) | “$28,859” | “$2,607” | “9.0%” |
| Chemotherapy (n=77) | “$30,682” | “$3,944” | “12.9%” |
| Checkpoint inhibitors (n=145) | “$36,056” | “$4,158” | “11.5%” |
| Tebentafusp (n=39) | “$93,805” | “$6,746” | “7.2%” |
| Liver directed therapy (n=80) | “$35,509” | “$3,078” | “8.7%” |
Hospital resource use and inpatient costs in NHS England
Inpatient administration of tebentafusp during dose escalation in practice
Economic impact of metastatic uveal melanoma on families
Practical and financial support from family members
“About half of the patients described the support received from close family or friends as being important for emotional support, assisting in decision-making or practical support such as transport, finances, understanding of medical information, and support with activities of daily living when they were unwell. Of these patients, most specified their partner as their main source of support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, some of them expressed regret for the emotional and practical burden their disease and treatment conferred to their family” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Travel and accommodation costs of treatment at specialist centers
“Some treatments required patients to travel interstate or even overseas to access them, in two cases separating women from their family for long periods. In these instances, financial burden from travel and accommodation became a significant issue.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Concern about the financial burden of self-funded treatment on the family
“Aside from uncertainty, participant concerns focused largely on time, travel and financial burdens from new generation treatments, which were available only at specialist cancer centres and rarely subsidised by government schemes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants expressed worry about their ability to self-fund treatment and the potential they might have to decide whether to pursue expensive new treatments if their current one failed, especially the financial burden this might place on their family for increasingly uncertain gains with each new line of therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Payment rates for HLA class I typing and uveal melanoma gene expression profiling on a 2026 state Medicaid laboratory fee schedule
| Test | Code | Description | Rate |
|---|---|---|---|
| HLA class I typing, high resolution, one locus | “81380” | “HLA CLASS I TYPING HIGH RESOLUTION ONE LOCUS” | “$177.25” |
| HLA class I typing, high resolution, one allele or allele group | “81381” | “HLA CLASS I TYPING HIGH RESOLUTION ONE ALLELE OR ALLELE GROUP” | “$169.90” |
| Gene expression profiling of uveal melanoma, 15 genes | “81552” | “MRNA GENE EXPRESSION ANALYSIS OF 15 GENES IN EYE MELANOMA O TISSUE OR FINE NEEDLE ASPIRATE” | “$7,776.00” |
HLA-A∗02:01 test at a U.S. reference laboratory: billing code, method, specimen, and turnaround
| Item | Labcorp test 167107, HLA A A∗02:01-Specific |
|---|---|
| CPT code | “81381” |
| Methodology | “Next Generation Sequencing (NGS), sequence-based typing (SBT) or other DNA methods as needed to achieve desired resolution” |
| Result turnaround time | “3 - 7 days” |
| Specimen | “Whole blood, buccal swabs, spot cards or extracted DNA” |
| Regulatory status | “This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.” |
HLA-A∗02:01 status recorded in a U.S. real-world cohort
Medicare coverage of gene expression profiling of the primary tumor
Medicare payment rate and annual volume of the DecisionDx-UM test
Biopsy, prognostic genetic testing, and out-of-pocket payment reported in a Canadian patient and caregiver survey
Surveillance intensity by metastatic risk class and modeled reduction in surveillance procedures
Liver surveillance imaging volume and modeled savings from risk-based screening in the United Kingdom
“A total of 3854 liver scans were performed on the 615 patients, with a median of 6.2 scans per patient (range, 1–40). Liver MRI was the most performed modality, 2419 scans (63%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Results showed that at 80% sensitivity, 87% of UM patients will avoid unnecessary radiological scans. This provides potential cost savings of between £46,000 and £97,000 per year to the National Health Service assuming 600 new cases per year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
Bispecific t-cell receptor therapy
Tebentafusp: IMCgp100-202 primary analysis of overall survival in the intention-to-treat population of 378 participants
“A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: IMCgp100-202 control arm composition and dosing
“Of the 378 eligible HLA-A*02:01–positive patients, 252 were randomly assigned to the tebentafusp group and 126 to the control group; of the patients in the control group, 103 (82%), 16 (13%), and 7 (6%) were assigned to receive pembrolizumab, ipilimumab, and dacarbazine, respectively (Fig. S1 in the Supplementary Appendix).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab was given intravenously at a dose of 2 mg per kilogram of body weight (with a maximum of 200 mg per dose) on day 1 of each 21-day cycle. Ipilimumab was administered intravenously at a dose of 3 mg per kilogram on day 1 of each 21-day cycle for a maximum of four doses. Dacarbazine was given intravenously at a dose of 1000 mg per square meter of body-surface area on day 1 of each 21-day cycle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: IMCgp100-202 overall survival, progression-free survival, and response in the 3-year analysis
“In this 3-year analysis, the overall survival benefit continued to favor tebentafusp, with a stratified hazard ratio for death of 0.68 (95% CI, 0.54 to 0.87) (Fig. 1A). Median overall survival was 21.6 months (95% CI, 19.0 to 24.3) in the tebentafusp group and 16.9 months (95% CI, 12.9 to 19.5) in the control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The percentage of patients who were surviving at 1, 2, and 3 years among those treated with tebentafusp was 72%, 45%, and 27%, respectively, as compared with 60%, 30%, and 18% among the patients in the control group (Fig. 1A and Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was 3.4 months (95% CI, 3.0 to 5.4) in the tebentafusp group and 2.9 months (95% CI, 2.8 to 3.0) in the control group (stratified hazard ratio for progression or death, 0.76; 95% CI, 0.60 to 0.97) (Fig. 1B and Table S4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With extended follow-up, the percentage of patients who had an objective response continued to be higher in the tebentafusp group than in the control group (11% vs. 5%), with five additional patients in the tebentafusp group having a partial response since the previous analysis (Table 1 and Fig. S5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: IMCgp100-202 treatment beyond progression, crossover, and survival with progressive disease as best response at 3 years
“More than half the patients who received treatment in the tebentafusp group (139 of 245 [57%]) were treated beyond initial radiographic progression, as compared with a quarter of the patients in the control group (28 of 111 [25%]). Sixteen patients in the control group crossed over to receive tebentafusp after the primary analysis (Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When this analysis was repeated with data from patients who crossed over to the tebentafusp group censored at the start of treatment with tebentafusp, the effect on the hazard ratio for death was minimal (0.70; 95% CI, 0.54 to 0.90).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a 100-day landmark analysis involving the patients who had a best overall response of progressive disease by day 100 after randomization, postlandmark overall survival was longer in the tebentafusp group than in the control group (Fig. 2, Table S6, and Figs. S8 and S9). The hazard ratio for death in this analysis was 0.62 (95% CI, 0.44 to 0.89) in favor of tebentafusp.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: IMCgp100-202 cytokine release syndrome by ASTCT grade and treatment-related discontinuation at 3 years
“cytokine release syndrome, which was graded post hoc, occurred in 89% of tebentafusp-treated patients and was most frequent in the first 4 weeks of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most of the patients who had cytokine release syndrome (88%) had grade 1 (12%) or 2 (76%) as the maximum grade, although some patients (1%) had a grade 3 event.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3 or 4 treatment-related adverse events occurred in 116 patients (47%); the most common were rash (19%) and an elevation in the aspartate aminotransferase level (6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No new treatment-related discontinuations were reported: during the trial, 2% of the patients in the tebentafusp group and 5% of those in the control group discontinued treatment because of adverse events that were related to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: IMCgp100-202 final 5-year overall survival
Tebentafusp: IMCgp100-202 survival with progression on tebentafusp and treatment beyond radiographic progression at 5 years
HLA-A∗02:01 restriction: proportion of HLA-A∗02:01-negative patients at IMCgp100-202 prescreening
Tebentafusp in previously treated disease: IMCgp100-102 response and survival
“Despite a low overall response rate of 5% (95% CI: 2–10%), the 1 year overall survival rate was 62% (95% CI: 53–70%) with a median overall survival of 16.8 months (95% CI: 12.9–21.3), suggesting benefit beyond traditional radiographic-based response criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than two-thirds of patients (n = 90) received prior immune checkpoint inhibition, of whom 68% had primary resistance to treatment with a prior best response of progressive disease, and 32% relapsed, with a prior best response of at least stable disease, following treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp in previously treated disease: IMCgp100-102 long-term survival in 146 treated participants
“146 patients were treated with tebentafusp: 19 in phase 1 and 127 in phase 2. With a median follow-up duration of 48.5 months, the median OS was 17.4 months (95% CI, 13.1 to 22.8), and the 1-year, 2-year, 3-year and 4-year OS rates were 62%, 40%, 23% and 14%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cytokine release syndrome: incidence, grade, and timing in a pooled analysis of 391 participants from IMCgp100-102 and IMCgp100-202
“Across both studies, most patients experienced at least one episode of CRS (n = 344 of 391; 88%), the majority of which were mild (grade 1, 19%) or moderate (grade 2, 67%) in severity (Fig. 2A; Supplementary Table S4). Most grade 2 CRS events (92%) were due to hypotension, whereas 4.5% of events were attributed to hypoxia and 3.6% involved both conditions. Only a few patients (n = 7, 2%) had grade 3 (n = 6) or grade 4 (n = 1) CRS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no instances of immune effector cell-associated neurotoxicity syndrome reported, and no deaths occurred as a result of CRS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients experienced CRS after each of the first three tebentafusp infusions, but both incidence and severity decreased with repeated dosing (Supplementary Fig. S3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cytokine release syndrome: management with antipyretics, fluids, and corticosteroids, and hospitalization in IMCgp100-202
“Unlike other trials of T-cell engagers, none of the three tebentafusp trials mandated any premedications as primary prophylaxis for CRS. The medications most frequently used to treat CRS were antipyretics (88%), intravenous fluids (45%), and systemic corticosteroids (25%; Table 3); four (1%) patients received tocilizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients with CRS (64%) received only a single dose of systemic corticosteroid to manage their CRS episodes, and in a post hoc propensity score analysis of IMCgp100-202, early corticosteroid use to manage AE did not negatively affect OS when adjusted for baseline prognostic factors (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a retrospective analysis of hospitalizations, defined as either an extension of the mandated monitoring period during intra-patient dose escalation or an unplanned hospitalization at any time, in IMCgp100-202, a similar percentage of patients experienced an SAE-related hospitalization in the tebentafusp arm (24%) as in the investigator’s choice control arm (23%; Supplementary Table S8). In the tebentafusp group, most (65%) SAE-related hospitalizations occurred during the intra-patient dose-escalation period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cytokine release syndrome: expert recommendations for post-dose monitoring and patient selection
“Patients in good clinical condition and with a low tumour burden are good candidates for tebentafusp treatment, particularly if treated as early as possible after the diagnosis of metastatic disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Postdose monitoring should thus focus on pyrexia and hypotension as the first symptoms of cytokine release. To minimise the risk of hypotension associated with CRS, patients should receive intravenous fluids before starting treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: survival by line of therapy and inpatient stay during dose escalation in a treated cohort
“71% of patients were treated in the first-line setting, with 94% having liver metastases. At a median follow-up of 12 months (range 0 to 34), mOS was 21 months (95% CI, 17 to NR), and mPFS was 2.76 months (95% CI, 2.53-3.22).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First-line tebentafusp was associated with a longer mOS of 22 months (95% CI, 18 months to NR), compared to a mOS of 16 months (95% CI 10 months to NR) in the second-line and beyond (Figure S7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The required inpatient stay within the dose escalation phase was generally brief, with a median of 3 cumulative number of nights as an inpatient for doses 1 to 3.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No ≥ grade 3 toxicity was observed beyond dose 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp in a cohort of 175 participants: toxicity, treatment beyond progression, and survival
“175 patients were included: 127 received first-line tebentafusp, 48 had prior immune checkpoint inhibitors and/or chemotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-two patients (18 %) developed transient grade 3-4 toxicity, mostly rash, 5 patients had grade 3 cytokine release syndrome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“76 patients (43 %) were treated beyond progression; 1 was the CR, 1 PR and 30 SD. Median progression-free survival (PFS) was 4 months (95 % CI 2.7-5.3), median OS was 20 months (95 % CI 15.3-24.6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: retrospective comparison of sequencing with immune checkpoint inhibitors
“Patients with HLA-A * 02:01 positive mUM, or metastatic GNA11/GNAQ mutant melanocytic tumors treated with tebentafusp followed by ICIs (group 1) or the inverse sequence (group 2) at any treatment line were retrospectively identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 22.4 months (95 % CI 19-24.8) in group 1 and 33.6 months (95 % CI 28.9-43) in group 2 (p = 0.004).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This observation is limited by the retrospective nature of the study and merits further investigation in prospective clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp versus nivolumab plus ipilimumab: propensity score-weighted comparison of IMCgp100-202 and GEM1402
“In the single-arm GEM1402 (N = 52), the 1-year OS rate for nivolumab plus ipilimumab (N+I) in mUM was 52%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The IPTW-adjusted OS favored tebentafusp, HR 0.52 [95% confidence interval (CI) 0.35-0.78]; 1-year OS was 73% for tebentafusp versus 50% for N+I.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“IPTW analysis of pembrolizumab versus N+I showed no significant difference in OS (HR 0.72; 95% CI 0.50-1.06).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: guideline recommendation for HLA-A∗02:01-positive metastatic disease
“For HLA-A∗02:01-positive patients, tebentafusp should be standard of care in the first-line metastatic setting unless liver-directed treatment modalities are required first for tumour debulking [I, A; ESMO-Magnitude of Clinical Benefit (ESMO-MCBS) v2.0 score: 3].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If these patients progress, liver-directed treatment modalities, anti-PD-1-based immunotherapies and clinical trial enrolment are the preferred therapeutic options [V, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: NICE recommendation and clinical findings
Tebentafusp: CADTH recommendation, clinical findings, and inpatient monitoring for initial doses
Immune checkpoint inhibitors
Guideline recommendation on combination immunotherapy and patient selection
“Given the lack of a clear survival advantage in metastatic UM associated with nivolumab–ipilimumab versus pembrolizumab and the increased toxicity associated with the former, only selected patients fit enough for the combination and with predominant extrahepatic disease should be considered for the combination immunotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline summary of anti-PD-1 monotherapy outcomes in uveal melanoma
“Patients with metastatic UM have been excluded from most trials evaluating ICIs in cutaneous melanoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the safety profile of PD-1 inhibitors was better in UM compared with cutaneous melanoma, efficacy was comparatively disappointing, showing <5% ORR, median PFS of 3 months and 1-year OS ∼50%, likely due to low tumour mutational burden, poor antigen processing and presentation and the immune-suppressive tumour microenvironment in UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline summary of phase 2 trials of nivolumab plus ipilimumab
“In two phase II studies in 52 and 33 patients, respectively, nivolumab–ipilimumab was associated with ORR of 11% and 18%, median PFS of 3 and 5.5 months and median OS of 12 and 19 months, respectively, after a median follow-up of ∼13 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indirect comparison of tebentafusp, nivolumab plus ipilimumab, and pembrolizumab in first-line disease: guideline summary
“In the absence of randomised comparative studies, indirect comparisons of ICIs with tebentafusp in first-line metastatic UM have been conducted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A propensity score analysis of two studies showed an OS benefit for tebentafusp versus nivolumab–ipilimumab (1-year OS rate of 73% versus 50%, respectively), independent of HLA status, and no significant difference in survival between pembrolizumab and nivolumab–ipilimumab (median OS and 1-year OS rate of 16.9 months and 60% versus 14.2 months and 52%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Toxicity rates were higher with nivolumab–ipilimumab compared with pembrolizumab (23% versus 2%-5% treatment-related discontinuations and two versus no treatment-related deaths).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line nivolumab plus ipilimumab: single-arm phase 2 trial of the Spanish Multidisciplinary Melanoma Group, 52 participants
“This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-naïve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0/1, and confirmed progressive metastatic disease (M1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS and PFS were 12.7 months and 3.0 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Nivolumab plus ipilimumab: single-arm phase 2 trial of 35 participants
“This single-arm phase II study of nivolumab and ipilimumab in patients with metastatic uveal melanoma demonstrated an overall response rate (ORR) of 18%, a median progression-free survival of 5.5 months, and a median overall survival of 19.1 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 18%, including one confirmed complete response and five confirmed partial responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the 35 patients included in the study, the median OS was 19.1 months (95% CI, 9.6 months to NR), and the 1-year OS was 56% (95% CI, 38% to 71%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR in the 31 evaluable patients who were checkpoint naïve was 19%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nivolumab plus ipilimumab in practice: multicenter retrospective study of 89 participants
“We conducted a retrospective analysis of patients with metastatic UM (mUM) who received treatment with ipilimumab plus nivolumab across 14 academic medical centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“89 eligible patients were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall response rate was 11.6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS from treatment initiation was 15 months and median PFS was 2.7 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ipilimumab plus a PD-1 inhibitor at 16 German skin cancer centers: 64 participants
“The clinical data of 64 patients from 16 German skin cancer centers who met the inclusion criteria were investigated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The best overall response rate to combined checkpoint blockade was 15.6% with 3.1 and 12.5% complete and partial response, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 3.0 months (95% CI 2.4–3.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was estimated to 16.1 months (95% CI 12.9–19.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line pembrolizumab: prospective observational cohort of 17 participants
“In this prospective observational cohort single arm study, we investigated efficacy and safety of Pembrolizumab as first-line therapy for mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seventeen patients were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two patients achieved partial response (11.7%), 6 a disease stabilization (35.3%), whereas 9 (53%) had a progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Toxicity was mild, without grade 3–4 side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PD-1 or PD-L1 antibody monotherapy: multicenter retrospective series of 56 participants
“Safety and clinical efficacy outcomes including best overall response (BOR), progression-free survival (PFS), overall survival (OS) were determined retrospectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we report clinical outcomes in a larger series of 56 patients treated at nine institutions with PD-1 (pembrolizumab or nivolumab) or PD-L1 (atezolizumab) antibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Objective tumor responses were observed in two patients for an overall response rate of 3.6% (95% CI 1.8-22.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 2.6 months (95% CI 2.4-2.8 months) and the median OS was 7.6 months (95% CI 0.7-14.6 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PD-1 inhibitor monotherapy at 20 German skin cancer centres: 86 participants
“Patients with metastatic UM treated with either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) were included from 20 German skin cancer centres.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eighty-six patients were treated with PD-1 inhibitors only (n = 54 for pembrolizumab, n = 32 for nivolumab) with a centrally confirmed response rate of 4.7%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 14 months for pembrolizumab-treated and 10 months for nivolumab-treated patients (p = 0.765).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ipilimumab monotherapy: phase 2 DeCOG trial in pretreated and treatment-naïve participants
“We performed an open-label, multicenter, single-arm phase II clinical trial (DeCOG-trial) to further evaluate the efficacy and safety of 3mg/kg ipilimumab in treatment-naïve and pretreated patients with advanced UM seen in daily routine in interdisciplinary skin cancer units in Germany.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Forty five pretreated (85%) and eight treatment-naïve (15%) patients received at least one dose of ipilimumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 6.8 months (95% CI 3.7–8.1), median progression-free survival 2.8 months (95% CI 2.5–2.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen patients had stable disease (47%), none experienced partial or complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related AEs were observed in 35 patients (66%), including 19 grade 3–4 events (36%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ipilimumab monotherapy after prior treatment: expanded access program of 82 assessable participants
“Pre-treated patients with advanced uveal melanoma received ipilimumab 3 mg/kg through an expanded access programme, every 3 weeks for four doses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 82 assessable patients, 4 (5%) had an immune-related objective response and 24 (29%) had immune-related stable disease lasting ≥3 months for an immune-related disease control rate of 34%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With a median follow-up of 5.6 months, median overall survival (OS) was 6.0 months and median progression-free survival (PFS) was 3.6 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of response and survival by checkpoint inhibitor class
“Pooled ORR was 9.2% overall (95% CI 7.2-11.8) [4.1% for anti-CTLA4 (95% CI 2.1-7.7), 7.1% for anti-PD(L)1 (95% CI 4.5-10.9) and 13.5% for anti-CTLA4 plus anti-PD1 (95% CI 10.0-18.0)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 11.5 months overall (95% CI 9.5-13.8) [8.0 months for anti-CTLA4 (95% CI 5.5-9.9), 11.7 months for anti-PD(L)1 (95% CI 9.0-14.0) and 16.0 months for ipilimumab plus anti-PD1 (95% CI 11.5-17.7) ( P < 0.001)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS was 3.0 months overall (95% CI 2.9-3.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver-directed therapies
Guideline recommendations for surgical resection, thermal ablation, and stereotactic radiotherapy
“Patients with oligometastatic UM with metastases confined to the liver can be considered for surgical resection and/or local liver-directed therapies (thermal ablation with radiofrequency, cryoablation or microwave ablation) [IV, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“SRT could be an alternative in patients not eligible for surgery or thermal ablation [IV, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Preoperative MRI can be recommended as well as laparoscopy before or at the time of planned resection [IV, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendations for regional hepatic perfusion
“Patients with multifocal liver metastases confined to the liver should be considered for regional liver-directed therapies (PHP or IHP) [II, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with liver-dominant disease and a good general condition can be considered for regional treatment at any line of metastatic recurrence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The melphalan for Injection/Hepatic Delivery System, recently approved by the Food and Drug Administration (FDA), may be considered an option in patients with HLA-A∗02:01-negative UMLMs and limited tumour burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Liver-directed options listed in the NCCN guidelines, as summarized by the FOCUS investigators
“the National Comprehensive Cancer Network guidelines recommend for those patients, among other options, liver-directed therapies, including transarterial chemoembolization (TACE), radioembolization or immunoembolization, and thermal ablation, as well as locoregional perfusion procedures delivering high-dose chemotherapeutic agents, namely, intrahepatic perfusion (IHP), a surgical procedure, and percutaneous hepatic perfusion (PHP), a minimally invasive procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Melphalan percutaneous hepatic perfusion: single-arm phase 3 FOCUS study, treated population of 91 participants
“The multicenter, open-label, phase 3 FOCUS study was designed to evaluate the efficacy and safety of melphalan/HDS in patients with unresectable mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to slow enrollment, with patient reluctance to receive BAC treatment, the study design was amended to a single-arm study, after which all eligible patients received treatment with melphalan/HDS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible patients with mUM received treatment with melphalan (3.0 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of six cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study enrolled 102 patients with mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the treated population ( n = 91), the ORR was 36.3 % (95 % confidence interval [CI], 26.44–47.01), including 7.7 % of patients with a complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median DOR was 14 months, and the median OS was 20.5 months, with an OS of 80 % at 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 9 months, with a PFS of 65 % at 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selection criteria in the FOCUS study: liver involvement up to 50 percent
“The study population included male and female patients 18 years of age or older with histologically verified mUM to the liver; liver tumor involvement of up to 50 %; at least one measurable liver lesion as assessed by contrast-enhanced computed tomography (CT) scans of the chest, abdomen, and pelvis as well as contrast-enhanced MRI of the liver (and brain and bone scans when indicated)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The eligibility criteria were designed to minimize the risks associated with the procedure (e.g., exclusion of patients with moderate or severe liver cirrhosis, portal hypertension, or New York Heart Association [NYHA] II–IV status).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Melphalan percutaneous hepatic perfusion versus best alternative care: randomized portion of FOCUS, 85 participants
“The multicenter, open-label, Phase 3 FOCUS study was designed to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable mUM in comparison to best alternative care (BAC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to slow enrollment and patient reluctance to receive BAC treatment, the study design was amended to a single-arm Melphalan/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study enrolled 85 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible patients were randomized to receive Melphalan/HDS ( n = 43) or BAC ( n = 42), and 72 patients received study treatment (Melphalan/HDS [ n = 40]; BAC [ n = 32]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serious adverse events (SAEs) occurred in 51.2% of Melphalan/HDS and in 21.9% of BAC patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Melphalan percutaneous hepatic perfusion versus best available care: earlier randomized phase 3 trial of 93 participants
“A total of 93 patients were randomized to PHP-Mel ( n = 44) or BAC ( n = 49).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This randomized, phase III study demonstrated the efficacy of the PHP-Mel procedure.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“hPFS was 7.0 months for PHP-Mel and 1.6 months for BAC ( p < 0.0001), while oPFS was 5.4 months for PHP-Mel and 1.6 months for BAC ( p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was not significantly different (PHP-Mel 10.6 months vs. BAC 10.0 months), likely due to crossover to PHP-Mel treatment (57.1 %) from the BAC arm, and the hOR was 36.4 % for PHP-Mel and 2.0 % for BAC ( p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Isolated hepatic perfusion versus best alternative care: randomized phase 3 trial, response and progression-free survival
“In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with histologically or cytologically confirmed liver metastases from uveal melanoma were eligible if they had measurable disease according to RECIST version 1.1 criteria, had received no previous therapy for melanoma metastases (ie, first-line therapy), and had no evidence of extrahepatic disease by positron emission tomography-computed tomography (CT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively ( P < .0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 7.4 months versus 3.3 months ( P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months ( P < .0001), both favoring the IHP arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was one treatment-related death in the IHP group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Isolated hepatic perfusion versus best alternative care: SCANDIUM final overall survival
“In this phase III randomized controlled multicenter trial (the SCANDIUM trial), patients with previously untreated isolated uveal melanoma liver metastases were included between 2013 and 2021, with at least 24 months of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint was the 24-month OS rate, with the hypothesis of a treatment effect leading to a 50% OS rate in the IHP group compared to 20% in the control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 24-month OS rate was 46.5% in the IHP group versus 29.5% in the control group ( P =0.12).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was 21.7 months versus 17.6 months, with a hazard ratio of 0.64 (95% CI, 0.37–1.10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Percutaneous hepatic perfusion with or without ipilimumab plus nivolumab: single-centre randomized phase 2 trial
“In this investigator-initiated, single-centre, open-label, randomised, phase 2 trial, adults aged 18-80 years with unresectable liver-only or liver-dominant metastatic uveal melanoma, WHO performance status 0-1, and with no previous systemic therapy were randomly assigned (1:1) to receive percutaneous hepatic perfusion alone (perfusion group) or percutaneous hepatic perfusion combined with ipilimumab plus nivolumab (combination group).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“1-year progression-free survival was 54·7% (95% CI 36·8-69·5) with combination therapy versus 15·8% (5·8-30·1) with perfusion alone (adjusted hazard ratio 0·34 [95% CI 0·19-0·60]; p=0·0002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3-4 treatment-related adverse events occurred in 31 (82%) of 38 patients with combination therapy compared to 15 (41%) of 37 patients with perfusion alone, due to both a higher incidence of severe perfusion-related events and immunotherapy-related adverse events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One treatment-related death (due to triple M syndrome) occurred in the combination group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Surgical resection of liver metastases: outcomes and selection criteria in the guideline
“Retrospective cohorts have reported a median OS of 14-29 months after surgery of UMLMs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival (PFS) and OS after resection with curative intent are 12 months and 26 months, respectively, with reported 5-year survival rates of ∼35% in highly selected patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surgery with curative intent (R0 resection) is the treatment of choice when the disease-free interval from primary tumour diagnosis to liver metastases is >24 months, and the number of metastases is ≤4 in the absence of miliary disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surgical resection of liver metastases: single-institution series of 255 resected participants
“To review the evolving surgical management of this challenging condition at a single institution over a 16-year period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“255 patients underwent surgical resection.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median overall postoperative survival was 14 months, but increased to 27 months when R0 resection was possible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With multivariate analysis, four variables were found to independently correlate with prolonged survival: an interval from primary tumour diagnosis to liver metastases >24 months, comprehensiveness of surgical resection (R0), number of metastases resected (< or = 4) and absence of miliary disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Surgical resection of metastases in highly selected patients
Thermal ablation compared with resection
“Compared with liver resection, cryoablation, microwave or radiofrequency ablation is associated with lower complication rates, lower costs, shorter hospital stays and faster patient recovery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A retrospective study comparing resection and percutaneous ablation in 57 and 15 patients, respectively, found no difference in median OS (27 months versus 28 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic arterial infusion, transarterial chemoembolization, and radioembolization: guideline summary
“In hepatic arterial infusion (HAI), also known as intra-arterial or transarterial ChT, ChT is administered through a catheter placed in the hepatic artery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Many cytotoxic agents have been tested, with fotemustine being the most active.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Studies investigating TACE in patients with UMLMs are limited to retrospective and small phase II trials and vary widely in the type of cytotoxic drugs and embolic agents used, the number of procedures per patient and patient selection criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The larger studies reported ORRs of 14%-46%, median PFS of 3-8 months and median OS of 5-29 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In transarterial radioembolisation (TARE), microspheres labelled with yttrium-90 or holmium-166 have been studied in retrospective and small prospective series; median PFS was 5.4 months and median OS was 12.3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunoembolization with GM-CSF versus bland embolization: randomized phase 2 trial of 52 participants with liver-only metastases
“To investigate the effects of immunoembolization with granulocyte–macrophage colony-stimulating factor (GM-CSF) in patients with uveal melanoma (UM) with liver-only metastasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this double-blind phase II clinical trial, patients were randomized to undergo immunoembolization or bland embolization (BE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty-two patients (immunoembolization, n = 25; BE, n = 27) were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were five partial responses in the immunoembolization group (ORR, 21.2%; 90% confidence interval [CI], 10.3%–30.5%) and three in the BE group (ORR, 16.7%; 90% CI, 6.3%–26.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OS times were 21.5 months (95% CI, 18.5–24.8 mo) with immunoembolization and 17.2 months (95% CI, 11.9–22.4 mo) with BE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Yttrium-90 radioembolization: prospective phase 2 trial
“In a prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastases, treatment-naïve participants (n = 24) achieved median overall survival of 18.5 months with a 1-year survival of approximately 61%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants treated with radioembolization in whom prior immunoembolization treatment failed (n = 23) achieved median overall survival of 19.2 months with a 1-year survival of approximately 70%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival with liver-directed treatment in an individual-patient meta-analysis of 29 trials
“Individual patient variables and survival outcomes were requested from 29 trials published from 2000 to 2016.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients treated with liver directed treatments had statistically significant longer PFS and OS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled overall survival by treatment modality compared with conventional chemotherapy
“Pooled OS reported after isolated hepatic perfusion [median OS: 1.34 years; hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.87–0.97, P = 0.0040], immunoembolization (median OS: 1.63; HR: 0.97, 95% CI: 0.95–1.00, P = 0.0080), and surgery (median OS: 1.43; HR: 0.94, 95% CI: 0.92–0.96, P < 0.0001) was longer, and after checkpoint inhibitor shorter (median OS: 0.59; HR: 1.13, 95% CI: 1.06–1.20, P < 0.0001) than after CHT (median OS: 0.91 years), but subject to identifiable confounding factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of liver-directed therapy: 55 studies of 2446 participants
“55 studies were included in the study, with 2446 patients treated overall.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Both surgery and liver-directed treatments were shown to have benefit in selected patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Substantial variability in patient selection and study design makes comparison of data and formulation of recommendations challenging.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cytotoxic chemotherapy
Guideline summary of chemotherapy in metastatic uveal melanoma
“Response rates are low (<10%) regardless of the cytotoxic agent tested and whether it was used as monotherapy or in combination.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drugs evaluated in this setting include dacarbazine, temozolomide, treosulfan, cisplatin and fotemustine” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“with no demonstrated OS benefit over best supportive care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pooled response to systemic treatment across 40 studies of 841 evaluable participants
“Complete or partial remissions were observed in 39/841 patients (overall response rate [ORR] 4.6%; 95% confidence intervals [CI] 3.3–6.3%), no responses were observed in 22/40 studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MUM is frequently treated with chemotherapeutics like dacarbazine, fotemustine, or gemcitabine/treosulfan although evidence for these regimens is limited.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Temozolomide or dacarbazine as the control arm of a randomized phase 2 trial of selumetinib
“Randomized open-label phase II clinical trial comparing selumetinib versus chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“101 patients were randomized on a 1:1 ratio to selumetinib 75 mg orally twice daily on a continual basis (n=50) or chemotherapy (temozolomide 150 mg/m2 orally daily for 5 of every 28 days or DTIC 1000 mg/m2 intravenously every 21 days; investigator choice; n=51) until disease progression, death, intolerable toxicity, or withdrawal of consent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival for those randomized to chemotherapy and selumetinib was 7 (95% CI, 4.3 – 8.4; median treatment duration of 8 weeks (IQR, 4.3–16)) and 15.9 weeks (95% CI, 8.4 – 21.1; median treatment duration of 16.1 weeks (IQR, 8.1–25.3)), respectively (hazard ratio 0.46; 95% CI, 0.30 – 0.71; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median overall survival was 9.1 (95% CI, 6.1 – 11.1) and 11.8 months (95% CI, 9.8 – 15.7) for those randomized to chemotherapy and selumetinib, respectively (hazard ratio 0.66; 95% CI, 0.41–1.06; p=0.09).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No objective responses were observed with chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Temozolomide or dacarbazine versus cabozantinib: randomized phase 2 Alliance A091201 trial
“Alliance for Clinical Trials in Oncology A091201, a randomized phase II trial of the multiple TKI cabozantinib that also inhibits MET and VEGFR2 compared with temozolomide (TMZ) or dacarbazine (DTIC) in patients with metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with metastatic UM and RECIST measurable disease were randomized 2:1 to receive either cabozantinib (arm 1) versus temozolomide or dacarbazine (arm 2) with restaging imaging every two cycles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rates of PFS4 in arm 1 and arm 2 were 32.3% and 26.7% (p=0.35), respectively, with median PFS time of 60 and 59 days (p=0.964; HR=0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median overall survival was 6.4 months and 7.3 months (p=0.580; HR=1.21), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade 3–4 CTCAE adverse events were present in 61.3%, 46.7%, and 37.5% in arms 1, 2 and 2X, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective response with placebo plus dacarbazine compared with selumetinib plus dacarbazine
Intravenous versus hepatic intra-arterial fotemustine: randomized phase 3 EORTC 18021 trial
“The prospective randomized phase III trial (EORTC 18021) thus aimed to compare the efficacy and safety of HIA versus IV fotemustine in UM patients with metastases in liver only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Accrual was stopped after randomization of 171 patients based on the results of a futility OS analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HIA did not improve OS (median 14.6 months) when compared with the IV arm (median 13.8 months), hazard ratio (HR) 1.09; 95% confidence interval (CI) 0.79–1.50, log-rank P = 0.59.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, there was a significant benefit on PFS for HIA compared with IV with a median of 4.5 versus 3.5 months, respectively (HR 0.62; 95% CI 0.45–0.84, log-rank P = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An improved RR was seen in the HIA (10.5%) compared with IV treatment (2.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main grade ≥3 toxicity related to HIA was catheter complications (12%) and liver toxicity (4.5%) apart from two toxic deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Temozolomide: phase 2 trial of 14 participants with liver metastases
“we conducted a phase II clinical trial of temozolomide in patients with uveal melanoma metastatic to the liver.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fourteen patients were enrolled in the trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No complete or partial responses were observed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that, like DTIC, temozolomide at the dose and schedule studied in this trial is not effective for the control of metastatic melanoma of uveal origin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Temozolomide plus bevacizumab: noncomparative phase 2 study of 36 participants
“This noncomparative phase II study evaluated a combination of bevacizumab (10 mg/kg on days 8 and 22) with temozolomide (150 mg/m 2 on days 1–7 and 15–21) in 36 patients with metastatic uveal melanoma (MUM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS and OS were 12 weeks and 10 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with MUM, a combination of bevacizumab plus temozolomide achieved a 6-month PFR of 23%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cisplatin, dacarbazine, and vinblastine as first-line treatment for unresectable metastases: phase 2 study
“In the present phase II study we administered intravenously cisplatin (80 mg/mq, day 1), dacarbazine (250 mg/mq/day, days 1-3), vinblastine (2 mg maximum, day 1) every 21 days as first line treatment for patients with unresectable metastases of uveal melanoma and BRAF wild type.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Partial responses were observed in five (20%) patients, stable disease in 12 (48%) patients; disease control rate was 68%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS of all the patients was 13 months, median progression free survival was 5.5 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Five (20%) patients experienced grade 3-4 toxicity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Chemotherapy in the control group of a randomized trial of isolated hepatic perfusion
“In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These disappointing outcomes reflect generally poor responses to systemic chemotherapy, which shows minimal efficacy and delivers no detectable survival benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Targeted therapies and clinical trial enrollment
Guideline recommendation of clinical trial enrollment for HLA-A∗02:01-negative patients
“For HLA-A∗02:01-negative patients, in the absence of a standard of care and depending on local resources, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies and clinical trial enrolment are the preferred therapeutic options [V, B].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline statements on referral and access to clinical trials
“Patients should be referred for the recommendation of first-line locoregional or systemic treatment and discussion of UM clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Metastatic disease remains an area of high unmet need and requires ambitious research collaborations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients should have access to experimental treatments, including precision diagnostics and medicine and early-phase clinical trials for solid tumours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical trials as an option in metastatic and recurrent intraocular melanoma
MEK inhibitor selumetinib compared with chemotherapy: response, adverse events, and survival
“49% of patients treated with selumetinib achieved tumor regression, with 14% achieving an objective radiographic response to therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events were observed in 97% patients treated with selumetinib, with 37% requiring at least one dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this hypothesis-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy resulted in a modestly improved progression-free survival and response rate; however, no improvement in overall survival was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selumetinib plus dacarbazine versus placebo plus dacarbazine: phase 3 SUMIT trial of 129 participants
“The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21-day cycle) or placebo plus dacarbazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Selumetinib with or without paclitaxel: randomized SelPac trial of 77 participants
“Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS in the combination arms was 4.8 months (95% CI: 3.8 - 5.6) compared with 3.4 months (2.0 - 3.9) in the selumetinib arm (HR 0.62 [90% CI 0.41 - 0.92], 1-sided p-value = 0.022).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ORR was 14% and 4% in the combination and monotherapy arms respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SelPac met its primary endpoint, demonstrating an improvement in PFS for combination selumetinib and paclitaxel.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No improvement in OS was observed, and the modest improvement in PFS is not practice changing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of MEK inhibitors in metastatic uveal melanoma
“The overall response rate was available in five studies and ranged from 0 to 14% with an average of 2.5%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median progression-free survival ranged from 3.1 weeks to 16 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“UM is little responsive to MEK inhibition, regardless of the inhibiting agent and combination partner.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Our results do not support the use of MEK inhibitors in UM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Protein kinase C inhibitor AEB071 monotherapy: phase 1 study of 153 participants
“Patients with metastatic UM (n = 153) were treated with AEB071 in a phase I, single-arm study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Preliminary clinical activity was observed, with 3% of patients achieving a partial response and 50% with stable disease (median duration 15 weeks).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In conclusion, the protein kinase C inhibitor AEB071 was well tolerated, and modest clinical activity was observed in metastatic UM.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sotrastaurin plus the MEK inhibitor binimetinib: phase 1b trial of 38 participants
“We therefore conducted this phase Ib study of the combination of sotrastaurin and binimetinib in patients with metastatic uveal melanoma” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-eight patients were treated across six dose levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No patient achieved a radiographic response per RECIST v1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stable disease was observed in 60.5% of patients treated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sotrastaurin plus the PI3K-alpha inhibitor alpelisib: phase 1b study
“we conducted a phase Ib study to assess the safety of combined sotrastaurin, a PKC inhibitor, and alpelisib, a PI3K inhibitor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with metastatic uveal melanoma (n = 24) or GNAQ/11 mutant cutaneous melanoma (n = 1) were enrolled on escalating dose levels of sotrastaurin (100–400 mg BID) and alpelisib (200–350 mg QD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events (AE) occurred in 86% (any grade) and 29% (Grade 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No objective responses were observed, and median progression-free survival was 8 weeks (range, 3–51 weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Kinase inhibitors compared with chemotherapy across published studies
Limitations of current therapies
Summary: HLA restriction of tebentafusp and absence of approved therapy for HLA-A∗02:01-negative disease
Tebentafusp, the only FDA-approved systemic therapy for metastatic uveal melanoma, is approved by the FDA and the EMA as first-line systemic treatment for HLA-A∗02:01-positive patients, and only approximately 45% of individuals in the United States and Europe are HLA-A∗02:01-positive. HLA-A∗02:01-negative patients “continue to lack an established standard of care” and comprised 49% of individuals prescreened in the tebentafusp trial. There is no consensus on first-line systemic therapy for HLA-A∗02:01-negative patients; their current options are immune checkpoint inhibitors, “which are not specifically approved for mUM”, and participation in clinical trials, and the National Cancer Institute states that no effective method of systemic treatment has been identified for metastatic ocular melanoma. Within its eligible population, tebentafusp produced a 5-year overall survival rate of 16% versus 8% in the control group with an 11% overall response rate, almost all treated patients eventually progressed, and Piperno-Neumann et al. state that “a high unmet need remains”. Tebentafusp requires weekly intravenous administration with observation periods at initiation and inpatient monitoring for the first 3 to 4 infusions because of the risk of cytokine release syndrome, which occurred in 89% of tebentafusp-treated patients.
Summary: response, survival, and toxicity with immune checkpoint inhibitors
With PD-1 inhibitors in uveal melanoma, the objective response rate is below 5%, median progression-free survival 3 months, and 1-year overall survival approximately 50%. A meta-analysis reported a pooled objective response rate of 9.2% (4.1% for anti-CTLA4, 7.1% for anti-PD(L)1, and 13.5% for anti-CTLA4 plus anti-PD1) and a median overall survival of 11.5 months; a second meta-analysis of 1414 patients reported response rates of 3.4% with single-agent and 12.4% with dual checkpoint inhibition and median overall survival of 9.8 and 16.3 months. In two phase 2 trials of nivolumab plus ipilimumab, objective response rates were 11% and 18% and median overall survival 12 and 19 months. Pham et al. conclude that checkpoint inhibitors have limited efficacy in metastatic uveal melanoma. Dual checkpoint inhibition adds toxicity: in the 64 participants with metastatic uveal melanoma in CheckMate 401, 64% had grade 3-4 treatment-related adverse events and 30% discontinued; grade 3-4 treatment-related adverse events occurred in 40% of patients in one phase 2 trial and severe treatment-related adverse events in 39.1% of patients in a German series; 34 of 89 patients in a retrospective study across 14 academic medical centers discontinued for toxicity; and treatment-related discontinuation was 23% with nivolumab plus ipilimumab versus 2%-5% with pembrolizumab, without a clear survival advantage for the combination.
Summary: scope and risks of liver-directed therapy
Liver-directed therapy treats liver metastases alone: percutaneous hepatic perfusion “does not address extrahepatic disease”. Most patients have multifocal and small liver metastases, and around 10% are eligible for local therapy, with perioperative mortality and morbidity after surgery of approximately 2% and 14%. The FOCUS study of melphalan percutaneous hepatic perfusion enrolled patients with liver tumor involvement of up to 50% and excluded those with moderate or severe cirrhosis, portal hypertension, or NYHA II-IV status; grade 3 and 4 treatment-emergent adverse events occurred in 81.1% of patients, including thrombocytopenia in 54.7%, and 17.9% discontinued treatment because of them. In an earlier randomized trial, four deaths were attributed to melphalan percutaneous hepatic perfusion, and median overall survival did not differ significantly between arms (10.6 versus 10.0 months). Isolated hepatic perfusion is non-repeatable and carries higher morbidity and mortality, and in the SCANDIUM trial the primary endpoint was not met (24-month overall survival 46.5% versus 29.5%, P=0.12). Adding ipilimumab plus nivolumab to percutaneous hepatic perfusion raised grade 3-4 treatment-related adverse events from 41% to 82%.
Summary: outcomes with chemotherapy and earlier targeted therapies
Response rates to chemotherapy are below 10% regardless of the cytotoxic agent, with no demonstrated overall survival benefit over best supportive care. Across 40 studies, complete or partial remissions occurred in 39 of 841 patients (4.6%), with no responses in 22 of the 40 studies. In randomized trials, no objective responses were observed with temozolomide or dacarbazine and median overall survival was 9.1 months, the objective response rate with placebo plus dacarbazine was 0%, and median overall survival with temozolomide or dacarbazine was 7.3 months in another trial. In a literature review, systemic treatment was associated with response rates below 10%, median progression-free survival of 1.8-7.2 months, and median overall survival of 5.2-19.0 months, and pooled survival fell from 52% at 1 year to 25% at 2 years and 13% at 3 years. Among earlier targeted agents, selumetinib plus dacarbazine did not significantly improve progression-free survival over placebo plus dacarbazine, the response rate to MEK inhibitors averaged 2.5% (range 0 to 14%), and 3% of 153 participants achieved a partial response with the protein kinase C inhibitor AEB071. A standard of care has not been defined despite numerous phase 2 studies.
Response and survival with systemic treatment: guideline summary of a literature review
“According to findings from a literature review, systemic treatment of metastatic UM was associated with low response rates (<10%), low median PFS (1.8-7.2 months) and OS (5.2-19.0 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Few prospective studies have been published on this rare cancer, especially randomised controlled trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No consensus on first-line systemic therapy for HLA-A∗02:01-negative disease
Unmet need and treatment options for HLA-A∗02:01-negative patients after the five-year tebentafusp analysis
Proportion of patients eligible for tebentafusp by HLA-A∗02:01 status
Decline in pooled overall survival from 1 to 3 years across treatment modalities
“The median OS was 1.07 years (95% CI: 1.00–1.13), but the survival rate decreased rapidly from 52% (95% CI: 50–54) at 1 year to 25% (95% CI: 23–26) at 2 years, and 13% (95% CI: 12–15) at 3 years (Table 1 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limited efficacy of immune checkpoint inhibitors in meta-analysis
Pooled response and survival with immune checkpoint inhibitors in 1414 participants
“A random-effect model meta-analysis with generic inverse-variance was conducted, and 36 articles representing 41 cohorts of 1414 patients with metastatic uveal melanoma were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to single-agent ICI, dual ICI led to better ORR (single-agent: 3.4% [95% CI 1.8–5.1]; dual-agent: 12.4% [95% CI 8.0–16.9]; P < 0.001), DCR (single-agent: 29.3%, [95% CI 23.4–35.2]; dual-agent: 44.3% [95% CI 31.7–56.8]; P = 0.03), and OS (single-agent: 9.8 months [95% CI 8.0–12.2]; dual-agent: 16.3 months [95% CI 13.5–19.7]; P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Toxicity of nivolumab plus ipilimumab in the uveal melanoma subgroup of CheckMate 401: guideline summary
“In the subgroup of 64 patients with metastatic UM from CheckMate 401, ORR was 9% and median OS was 15 months; nivolumab–ipilimumab was associated with 64% grade 3-4 TRAEs, leading to discontinuation in 30% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 to 4 treatment-related adverse events with nivolumab plus ipilimumab
Treatment discontinuation for toxicity with nivolumab plus ipilimumab
“Overall, 82 (92%) of patients discontinued treatment, 34 due to toxicity and 27 due to progressive disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dual checkpoint inhibition yielded higher response rates than previous reports of single-agent immunotherapy in patients with mUM, but the efficacy is lower than in metastatic CM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severe treatment-related adverse events with combined checkpoint blockade
Liver-confined scope of percutaneous hepatic perfusion
Procedural risks of hepatic perfusion: guideline statements
“The expected benefit should be weighed against the risk of AEs (haematological complications mostly), but serious cardiovascular and thromboembolic complications may occasionally occur.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The efficacy of IHP is similar to PHP, but IHP is non-repeatable and is associated with higher morbidity and mortality rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 to 4 adverse events and discontinuation with melphalan percutaneous hepatic perfusion, and morbidity of isolated hepatic perfusion
“Grades 3 and 4 TEAEs were reported in 81.1 % of the patients including grade 3 or 4 thrombocytopenia (54.7 %), leukopenia (33.7 %), anemia (32.6 %), and neutropenia (29.5 %) (Table 3 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment was discontinued for 17.9 % of the patients due to TEAEs (Table 3 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although IHP treats the whole liver and has shown promising tumor response rates, its use is restricted by a high risk of morbidity and mortality due to its invasive nature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Deaths attributed to melphalan percutaneous hepatic perfusion
Overall survival primary endpoint not met with isolated hepatic perfusion
Eligibility for and morbidity of local treatment of liver metastases
“Most patients with UMLMs have multifocal and small metastases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Around 10% of the patients are eligible for local therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Perioperative mortality and morbidity rates after surgery of UMLMs are ∼2% and ∼14%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: target population
The FDA has agreed to review the new drug application for darovasertib in combination with crizotinib for patients with first-line HLA-A∗02:01-negative metastatic uveal melanoma under the Real-Time Oncology Review program, and the submission includes data from OptimUM-02 and OptimUM-01. OptimUM-02 enrolled adults 18 years and older with histologically or cytologically confirmed metastatic uveal melanoma that is HLA-A∗02:01 negative, no prior systemic therapy in the metastatic or advanced setting and no prior regional or liver-directed therapy (ablation or resection of oligometastatic disease and neoadjuvant or adjuvant therapy were allowed), measurable disease per RECIST 1.1, ECOG performance status 0 or 1, and a life expectancy of at least 3 months. Participants could be initially diagnosed with metastatic disease or have metastases after therapy for localized uveal melanoma. The trial excluded prior treatment with a PKC inhibitor or an inhibitor directly targeting MET, symptomatic or untreated CNS metastases, a high risk of syncope or falls, stroke within the last 6 months, and clinically significant cardiac disease. OptimUM-01 data, including the phase 2 expansion in 101 HLA-A∗02:01-positive participants, are intended to support discussions on expanding the labeled indication. Crizotinib is FDA approved for ALK- or ROS1-positive metastatic non-small cell lung cancer, ALK-positive anaplastic large cell lymphoma, and ALK-positive inflammatory myofibroblastic tumor. Identifying the population requires HLA-A∗02:01 typing, which a reference laboratory reports in 3 to 7 days; in a deidentified database of 219 patients, HLA-A∗02:01 status was negative in 42.9% and unknown in 15.1%.
Summary: position relative to current first-line therapy by HLA status and disease distribution
For HLA-A∗02:01-positive patients, tebentafusp is approved by the FDA and the EMA as first-line systemic treatment and is recommended as standard of care in the first-line metastatic setting unless liver-directed treatment is required first for tumour debulking. For HLA-A∗02:01-negative patients, in the absence of a standard of care, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies, and clinical trial enrolment are the preferred options; patients with extensive disease are encouraged to enter a clinical trial, with percutaneous hepatic perfusion or checkpoint inhibitors alone or in combination as alternatives, and local therapies are proposed for limited hepatic metastases. By disease distribution, oligometastatic disease confined to the liver can be considered for resection or thermal ablation, and multifocal metastases confined to the liver for regional perfusion.
Darovasertib plus crizotinib would enter first-line treatment of HLA-A∗02:01-negative disease. In 313 participants of the phase 2b/3 portion of OptimUM-02, the combination reduced the risk of progression by blinded independent central review by 58% (hazard ratio 0.42; 95% CI 0.30 to 0.59) compared with investigator's choice of pembrolizumab, ipilimumab plus nivolumab, or dacarbazine, with median progression-free survival of 6.9 versus 3.1 months. Dr. Lutzky stated that tebentafusp remains the preferred first-line therapy for HLA-A∗02:01-positive disease, that darovasertib plus crizotinib may become an alternative for selected patients with rapidly progressive disease, extensive liver involvement, or a need for prompt tumor shrinkage, and the same report states that darovasertib plus crizotinib “appears likely to become the preferred systemic first-line option”; percutaneous hepatic perfusion remains important for liver-dominant disease with preserved hepatic function. Faculty in an OncLive report did not support combining darovasertib plus crizotinib with tebentafusp upfront because of overlapping toxicity, or frontline dual checkpoint inhibition outside a clinical trial. The ESMO 2026 poster authors describe the combination as a potential “new oral standard of care” in this setting, and IDEAYA cites OptimUM-01 in support of its potential for patients irrespective of HLA-A∗02:01 status and line of therapy. The progression-free survival data may enable an accelerated approval filing, with overall survival from a prespecified interim analysis expected in mid-2027 to support full approval.
Summary: anticipated use and care setting
The combination is taken orally: participants received darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily, the recommended phase 2 dose, whereas the crizotinib label recommends 250 mg twice daily for NSCLC and lists 200 mg twice daily as its first dose reduction; crizotinib capsules are taken with or without food. The sponsor states that “A daily oral targeted regimen has the potential to improve compliance”. Tebentafusp, by comparison, requires weekly intravenous administration with observation at initiation, inpatient monitoring for the first 3 to 4 infusions in an experienced institution before subsequent infusions in a community clinic, and considerable pharmacy resources to prepare each dose.
Expert panelists noted that an oral regimen “removes the referral-forcing function that intravenous therapies create”, while the combination carries nausea, vomiting, diarrhea, and edema that low-volume community centers may not be able to manage; one panelist proposed a mandatory link to an expert center with community physicians managing maintenance. The short half-life of the combination typically makes brief holds and dose reductions, with dietary counseling, sufficient to keep patients on therapy, and the mean delivered dose intensity was 80% or more. Supportive measures for orthostatic hypotension during initial dosing include adequate hydration, initial withholding of blood pressure medications, and avoiding abrupt posture changes. The crizotinib label calls for liver function tests every 2 weeks during the first 2 months and then monthly, and ECG and electrolyte monitoring in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or QT-prolonging medications; OptimUM-02 excluded strong CYP3A4/5 inducers or inhibitors and narrow therapeutic index CYP3A4/5 substrates. A 2026 guideline recommends discussing therapeutic options at an oncology or molecular tumour board in reference centres with expertise in uveal melanoma, and a community oncology practice reports treating metastatic uveal melanoma in most of its clinic locations, a disease a general oncologist may see only once every several years. Darovasertib is currently available only through clinical trials; IDEAYA has initiated planning for potential commercial operations and expects a moderately sized specialty sales force to reach the relevant specialists, and Servier will be responsible for commercialization outside the U.S.
Darovasertib plus crizotinib in the targeted agents section of the guideline
“An interim analysis of a phase II trial ( NCT03947385 ) evaluating darovasertib in combination with the mesenchymal-epithelial transition factor (c-MET) inhibitor crizotinib showed ORR of 31% in the first 35 assessable patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp as the approved first-line systemic treatment for HLA-A∗02:01-positive disease
“In 2021, tebentafusp demonstrated OS benefit in the HLA-A∗02:01-positive first-line population; 23 the first time a systemic treatment showed a survival benefit in metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tebentafusp has been approved by the FDA and the European Medicines Agency (EMA) as first-line systemic treatment in HLA-A∗02:01-positive patients with metastatic UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sequencing by HLA-A∗02:01 status in the French expert consensus guidelines
“Systemic therapy with tebentafusp is the standard of care for HLA-A*02:01-positive patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For HLA-A*02:01-negative patients with extensive disease, treatment options are limited.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“They are encouraged to participate in a clinical trial, alternatively, percutaneous hepatic perfusion, ICI alone or in combination can be proposed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Local therapies are proposed for patients with limited hepatic metastases, from liver surgery to isolated hepatic perfusion and chemoembolisation for patients with more extensive hepatic involvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinical trials for HLA-A∗02:01-negative patients and combination of tebentafusp with locoregional therapy in a 2026 review
“The first-line treatment for HLA-A*02:01-positive MUM patients of tebentafusp can be combined with locoregional therapies upfront or in case of oligoprogression on tebentafusp following multidisciplinary tumor board (MTB) discussion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HLA-A*02:01-negative MUM patients should be offered participation in clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Innovative drugs, such as DYP688 or the combination of darovasertib and crizotinib, are promising.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discussant view of first-line sequencing by HLA-A∗02:01 status after the OptimUM-02 presentation
Discussant statement that the question has shifted to sequencing
Expert workshop positions on darovasertib plus crizotinib, combination with tebentafusp, and first-line dual checkpoint inhibition
Oral administration, community management, and linkage to expert centers
Weekly intravenous tebentafusp with observation at initiation, as contrasted by the OptimUM-01 investigators
Inpatient and outpatient initiation of tebentafusp in practice
Treatment in community oncology practice and clinical pathways for a rare disease
Tumor board discussion in reference centers and access to expert centers
“Therapeutic options should be discussed at an oncology or molecular tumour board (MTB) in reference centres with expertise in UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MTB should at minimum include ophthalmologists (optionally), pathologists, interventional radiologists, liver surgeons, radiation and medical oncologists.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“National networks and patient advocacy groups may help facilitate patient access to expert centres and organise local patient care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor and investigator positioning as a first-line standard for HLA-A∗02:01-negative disease
Sponsor and investigator positioning across HLA-A∗02:01 status and lines of therapy
Heterogeneity of treatment effect
HLA-A∗02:01 status: confirmed response in first-line and any-line participants of OptimUM-01, August 2023
HLA-A∗02:01 status: sponsor summary of first-line activity in the pooled OptimUM-01 population
Line of therapy and hepatic-only disease: OptimUM-01 per-protocol efficacy population, March 2023 data cutoff
MET pathway activity and response to darovasertib monotherapy
GNAQ and GNA11 mutations as the shared target population of PKC inhibition
Tebentafusp: overall survival in prespecified and exploratory subgroups with extended follow-up
Tebentafusp: baseline factors associated with longer overall survival and with survival of at least 5 years
“The baseline factors that were most associated with longer overall survival during treatment with tebentafusp included an ECOG performance-status score of 0, levels of LDH and alkaline phosphatase in the normal range, a largest metastatic lesion that was less than 8 cm in diameter, and a longer time since primary diagnosis (Table S5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: disease volume and line of therapy as modifiers of benefit in expert discussion
Tebentafusp: circulating tumor DNA reduction at week 9 and overall survival, 3-year analysis
“In an exploratory analysis, 202 of the 252 patients in the tebentafusp group had baseline and week 9 serum samples that were obtained during treatment and were available for ctDNA analysis; 123 of the patients with a sample (61%) had at least one detectable uveal mutation at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Likewise, patients who had clearance of ctDNA by week 9 had longer overall survival than those without clearance (median overall survival, 29.6 months vs. 10.2 months) (Fig. 3B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival among the 99 patients who had a reduction of at least 50% in the ctDNA level was longer than that among the 24 patients who had a reduction of less than 50%, no change, or an increase in the ctDNA level (hazard ratio for death, 0.41; 95% CI, 0.25 to 0.67) (Fig. 3C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: circulating tumor DNA reduction by best response and baseline tumor burden, 5-year analysis
Tebentafusp: BAP1 loss in the control group
Tebentafusp: early rash as a predictor of overall survival
Immune checkpoint inhibitors: MBD4-deficient hypermutated tumors
“Here we present a metastatic uveal melanoma patient with an exceptional high sensitivity to a PD-1 inhibitor associated with outlier CpG>TpG mutation burden, MBD4 germline deleterious mutation, and somatic MBD4 inactivation in the tumor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In our series of 42 metastatic UM patients treated with PD1inh, only one (UVM_IC) achieved a tumor response (details in Methods)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 12 patients who received ICIs, nine received pembrolizumab, two ipilimumab plus nivolumab followed by nivolumab, and one pembrolizumab plus lenvatinib within the frame of the PLUME phase 2 trial (NCT05282901).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The overall response rate was 50% (two complete, four partial) with a disease control rate of 83%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, 73% of patients were progression free, and the estimated 2-year OS was 86%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our findings support further evaluation of MBD4 mutation as a predictive biomarker and suggest that ICIs should be considered as a preferred first-line option in MBD4-mutated mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immune checkpoint inhibitors: low tumor mutational burden in GNAQ- or GNA11-mutant tumors
Immune checkpoint inhibitors: liver metastasis volume and extrahepatic-only disease
“Notably, the patients who benefited either had no liver metastases or small volume disease whereas rapidly progressing patients had bulky liver involvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“(A) PFS for patients with extrahepatic-only sites of metastases versus liver metastases was 12.0 months versus 5.5 months (P = .0918).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-seven evaluable patients had liver metastases, of whom five (19%) had a PR and three (11%) had stable disease for 6 months or longer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with extrahepatic metastases only and treated with ipilimumab-nivolumab combination seem to have a better prognostic, the expected survival was 3.2 times higher than with any other systemic treatment (HR 0.28, 95% CI: 0.11–0.69).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immune checkpoint inhibitors: lactate dehydrogenase level and outcomes
“Normal LDH was associated with improved OS (p=0.026)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, elevated LDH was not associated with significantly worse PFS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lactate dehydrogenase and alkaline phosphatase as prognostic factors in the guideline
Care management intervention strategies
Management of darovasertib plus crizotinib toxicities through dose holds, dose reductions, dietary counseling, and expert-center linkage
Crizotinib label: patient counseling on hepatotoxicity, bradycardia, and blood pressure medications
Crizotinib label: patient counseling on vision disorders, drug interactions, and photosensitivity
Pharmacist-led interventions for oral anticancer therapy: systematic review and meta-analysis of 27 studies
“A total of 27 studies evaluating pharmacist-led interventions in patients receiving oral anticancer therapy were identified through systematic searches, including randomized controlled trials, non-randomized controlled trials, and cohort studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The study identified 11 pharmacist interventions distributed across four main domains, namely patient education and behavioral support, symptom and toxicity management, medication therapy management, and healthcare access support.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The meta-analysis revealed that pharmacist interventions tend to improve medication adherence and treatment persistence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, the impact on clinical endpoints and the incidence of drug-related problems remained heterogeneous.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: expert recommendations on liver value monitoring and the two major toxicities
“The safety profile of tebentafusp is manageable and includes two major pathologies: cytokine release syndrome (CRS) and skin-related events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The monitoring of liver values is crucial, as patients may experience an increase in transaminases, which can even manifest as tumour lysis syndrome.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Tebentafusp: symptomatic management of cytokine release in a 2026 systematic review
Tebentafusp: structured adverse event monitoring in community oncology practice
Tebentafusp: management of skin reactions
Immune checkpoint inhibitors: management of immune-related adverse events by grade
“The management of immune-related adverse events depends on their severity: in mild cases (grade 1), therapy can be continued with simple monitoring; in moderate cases (grade 2), therapy is temporarily suspended and oral corticosteroids are administered; in severe cases (grade 3 or 4), treatment is discontinued and high-dose corticosteroids are used, possibly with additional immunosuppressants such as infliximab for refractory colitis or mycophenolate for hepatitis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response assessment with RECIST, tumor growth rate, and circulating tumor DNA
Early palliative and supportive care in the guideline
“Early integration of palliative care is internationally recommended to facilitate the transition from curative to palliative care and to individualise the intensity of care for patients with cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It may include psychological support, nutrition and palliative care support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Surveillance for metastasis after treatment of the primary tumor at reference centers
“Prognostication and surveillance should be led by a specialist MTB with UM expertise in ophthalmology, liver imaging, surgery, medical oncology and supportive care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Surveillance strategies should be managed at reference centres [III, A].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk-based surveillance imaging after treatment of the primary tumor: North American Delphi consensus
“Intermediate-risk patients should be screened for metastatic disease with a minimum frequency of every 3–6 months for 5 years, thereafter annually for at least 10 years from diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High-risk patients should be screened for metastatic disease with a minimum frequency of every 3–6 months for years 1–5 and every 6–12 months for years 6–10.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In high-risk patients, the use of contrast-enhanced MRI abdomen is preferred over CT abdomen for surveillance of metastatic uveal melanoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although there was agreement that low-risk patients warrant surveillance, no consensus was reached on the optimal approach for this group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient education and patient organizations
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.